ISSN 1948-9358 (online)

World Journal of *Diabetes*

Monthly Volume 16 Number 10 October 15, 2025

Published by Baishideng Publishing Group Inc

World Journal of Diabetes

Contents

Monthly Volume 16 Number 10 October 15, 2025

EDITORIAL

Berezin AE. Early predictors of carotid atherosclerosis in patients with type 2 diabetes mellitus. *World J Diabetes* 2025; 16(10): 112631 [DOI: 10.4239/wjd.v16.i10.112631]

REVIEW

Zhang F, Ma HG, Zhang B, Jiang LL, Nie KY, Deng CL, Liu Y. Potential roles of histone deacetylases in diabetic wound healing. *World J Diabetes* 2025; 16(10): 108346 [DOI: 10.4239/wjd.v16.i10.108346]

Haris K, Long I. Role of astrocytes in diabetic neuropathy: Review of their involvement in disease mechanisms. *World J Diabetes* 2025; 16(10): 108714 [DOI: 10.4239/wjd.v16.i10.108714]

Mao JX, Chen S, Li JC, Wang H, Zhao MX. Exosomes from adipose-derived stem cells: A potential therapeutic strategy for diabetic foot ulcers. *World J Diabetes* 2025; 16(10): 109763 [DOI: 10.4239/wjd.v16.i10.109763]

Pierantoni M, Dell'Aira M, Grassilli S, Brugnoli F, Bertagnolo V. MicroRNA 375 and diabetes: A key regulator of β cell function and a promising non-invasive biomarker. *World J Diabetes* 2025; 16(10): 110097 [DOI: 10.4239/wjd.v16.i10.110097]

Kaymak D, Ozgu-Erdinc AS. Advances in gestational diabetes mellitus screening: Emerging trends and future directions. *World J Diabetes* 2025; 16(10): 111309 [DOI: 10.4239/wjd.v16.i10.111309]

Li ZP, Luo C, Yu XM, Ye LY, Sun D, Duan CZ, Xu SY, Zeng MQ, Xu H, Peng ZY, Wang P, Wang YB, Ruan WJ, Xue ME, Zhang CJ, He DJ. Diabetic bone fragility through advanced glycation end product-collagen axis: Mechanisms and therapy of sodium glucose cotransporter 2 inhibitors. *World J Diabetes* 2025; 16(10): 111813 [DOI: 10.4239/wjd.v16.i10.111813]

MINIREVIEWS

Đuzel Čokljat A, Grubić Rotkvić P, Čokljat D, Ferri Certić J, Babić Z. Epicardial adipose tissue in diabetic myocardial disorder: Role of echocardiography. *World J Diabetes* 2025; 16(10): 107640 [DOI: 10.4239/wjd.v16.i10.107640]

Punnose J. Maternal and neonatal outcomes according to the timing of diagnosis of gestational diabetes: A critical appraisal. *World J Diabetes* 2025; 16(10): 108254 [DOI: 10.4239/wjd.v16.i10.108254]

Ramos Fernandes VA, Mendes LR, Franco Netto ROR, Belozo FL, Bezerra AA, dos Santos CPC, Cruel PTE, Buchaim DV, Buchaim RL, da Cunha MR. Anti-inflammatory effects of cannabidiol in the treatment of type 1 diabetes: A mini review. *World J Diabetes* 2025; 16(10): 110041 [DOI: 10.4239/wjd.v16.i10.110041]

Martin-Rivera F, Alarcón-Gómez J, Rodrigo-Mallorca D, Saez-Berlanga A, Gargallo P, Chulvi-Medrano I. Impact of resistance exercise in type 1 diabetes pediatric patients. *World J Diabetes* 2025; 16(10): 111337 [DOI: 10.4239/wjd.v16.i10.111337]

World Journal of Diabetes

Monthly Volume 16 Number 10 October 15, 2025

Contents

ORIGINAL ARTICLE

Retrospective Cohort Study

Huang YC, Liao WL, Lin HJ, Huang YT, Chang YW, Yang JS, Weng AL, Tsai FJ. Polygenic risk score for predicting diabetic retinopathy in patients with type 2 diabetes: A twenty-year follow-up study. *World J Diabetes* 2025; 16(10): 110138 [DOI: 10.4239/wjd.v16.i10.110138]

Retrospective Study

Han WT, Zhao J, Feng WL, Ma WT. Type 2 diabetes complicated by dry eye syndrome: Analysis of dry eye symptoms, corneal neuropathy, and influencing factors. *World J Diabetes* 2025; 16(10): 109080 [DOI: 10.4239/wjd.v16.i10.109080]

Zhou C, Deng SD, Wang YR, Liu PX, Zhang HH. Risk factors for urosepsis in diabetic patients with renal and ureteral calculi: A retrospective study. *World J Diabetes* 2025; 16(10): 109181 [DOI: 10.4239/wjd.v16.i10.109181]

Li AQ, Zhang F. Blood glucose variability impacts heart rate dynamics in older type 2 diabetic and coronary heart disease patients. *World J Diabetes* 2025; 16(10): 110722 [DOI: 10.4239/wjd.v16.i10.110722]

Ge LC, Zhang YL, Peng GL, Long M, Jin T, Lu B, Shao JQ, Li X. Serum alpha-1-microglobulin as a predictor of multiple complications in type 2 diabetes mellitus patients. *World J Diabetes* 2025; 16(10): 111548 [DOI: 10.4239/wjd.v16.i10.111548]

Clinical Trials Study

Huang C, Liu HZ, Liang JB, Zhao W, Wang YS, Ruan LF, Zhuang WZ, Li YS, Wang Q, Tang YK. *In vitro* and clinical evaluation of platelet-rich plasma combined with angioplasty in diabetic foot treatment. *World J Diabetes* 2025; 16(10): 110631 [DOI: 10.4239/wjd.v16.i10.110631]

Observational Study

Li ZY, Yu HY, Liang H. Analysis of inflammatory response and its factors after dental implant surgery in patients with type 2 diabetes. *World J Diabetes* 2025; 16(10): 110140 [DOI: 10.4239/wjd.v16.i10.110140]

Xu H, He DJ, Luo C, Yu XM, Duan CZ, Sun D, Wu DJ, Mao XQ, Jiang WF. Association between uric acid to high-density lipoprotein ratio and mental health symptoms in people with type 2 diabetes. *World J Diabetes* 2025; 16(10): 110211 [DOI: 10.4239/wjd.v16.i10.110211]

Tao XY, Pan TR, Zhong X, Pan XY. Association between Zhejiang University index and metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus. *World J Diabetes* 2025; 16(10): 110406 [DOI: 10.4239/wjd.v16.i10.110406]

Basic Study

Yu JJ, Han JG, Tan Y, Xu JX, LeBlanc A, Keller BB, Huang J, Cai L. Right ventricular dysfunctions in type 1 diabetic mice: A longitudinal study. *World J Diabetes* 2025; 16(10): 109526 [DOI: 10.4239/wjd.v16.i10.109526]

Song SY, Shan CC, Zhou PP, Xu WL, Tan Y, Zhou XQ, Huang LJ, Yan QH, Yu JY. Nephroprotective mechanism of Kunkui Baoshen decoction in diabetic kidney disease: Targeting the HERC2/NCOA4-mediated autophagy-dependent ferroptosis pathway. *World J Diabetes* 2025; 16(10): 109568 [DOI: 10.4239/wjd.v16.i10.109568]

Zha DQ, Gao P, Wu XY. Nicotinamide mononucleotide protects against diabetic nephropathy *via* IL-6/Rab5-mediated crosstalk between proximal tubular epithelial cells and podocytes. *World J Diabetes* 2025; 16(10): 109782 [DOI: 10.4239/wjd.v16.i10.109782]

Xu FZ, Dou L, Wu X, Xia CX, Yu DN, Man Y, Shen T, Huang XQ. Exosomal transfer of miR-375-3p from pancreatic β cells to hepatocytes impairs hepatic glycogenesis *via* Rbpj repression. *World J Diabetes* 2025; 16(10): 109815 [DOI: 10.4239/wjd.v16.i10.109815]

SYSTEMATIC REVIEWS

Faisal A, Awais M, Tariq Z, Basit A, Abbas T, Farzeela F, Iftikhar A, Basil AM. Qualitative systematic review of the socioeconomic factors affecting type 2 diabetes management in Pakistan. *World J Diabetes* 2025; 16(10): 111102 [DOI: 10.4239/wjd.v16.i10.111102]

META-ANALYSIS

An XD, Duan LY, Zhang YH, Jia QY, Zhang YM, Qiao Y. Association between antidiabetic drugs and cancer risk in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis. *World J Diabetes* 2025; 16(10): 110174 [DOI: 10.4239/wjd.v16.i10.110174]

Kamrul-Hasan ABM, Pappachan JM, Nagendra L, Akter N, Jena S, Dutta D, Nair S. Role of automated insulin delivery in managing insulin-treated outpatients with type 2 diabetes: A systematic review and meta-analysis. *World J Diabetes* 2025; 16(10): 111230 [DOI: 10.4239/wjd.v16.i10.111230]

CASE REPORT

Butler PW, Légaré JF, White CW. Transient extreme insulin resistance in a patient requiring extracorporeal membrane oxygenation for cardiogenic shock: A case report. *World J Diabetes* 2025; 16(10): 111212 [DOI: 10.4239/wjd.v16.i10.111212]

ABOUT COVER

Editorial Board Member of *World Journal of Diabetes*, Samuel Trevino, PhD, Full Professor, Research Scientist, Clinical Biochemistry, University Autonomous of Puebla, Puebla 72000, Mexico. samuel_trevino@hotmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Diabetes* (*WJD*, *World J Diabetes*) is to provide scholars and readers from various fields of diabetes with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJD mainly publishes articles reporting research results and findings obtained in the field of diabetes and covering a wide range of topics including risk factors for diabetes, diabetes complications, experimental diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes, diabetic angiopathies, diabetic cardiomyopathies, diabetic coma, diabetic ketoacidosis, diabetic nephropathies, diabetic neuropathies, Donohue syndrome, fetal macrosomia, and prediabetic state.

INDEXING/ABSTRACTING

The *WJD* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2025 Edition of Journal Citation Reports® cites the 2024 journal impact factor (JIF) for *WJD* as 4.6; JIF without journal self cites: 4.3; 5-year JIF: 5.0; JIF Rank: 43/191 in endocrinology and metabolism; JIF Quartile: Q1; and 5-year JIF Quartile: Q1.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Zi-Hang Xu*; **Production Department Director:** *Xiao-Mei Zheng*; **Cover Editor:** *Jia-Ru Fan*.

NAME OF JOURNAL
World Journal of Diabetes

ISSN
ISSN 1948-9358 (online)

LAUNCH DATE
June 15, 2010

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Lu Cai, Md. Shahidul Islam, Michael Horowitz

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/1948-9358/editorialboard.htm

PUBLICATION DATE
October 15, 2025

COPYRIGHT
© 2025 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/GerInfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

© 2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: office@baishideng.com https://www.wjgnet.com

World Journal of Diabetes

Submit a Manuscript: https://www.f6publishing.com

World J Diabetes 2025 October 15; 16(10): 111309

DOI: 10.4239/wjd.v16.i10.111309

ISSN 1948-9358 (online)

REVIEW

Advances in gestational diabetes mellitus screening: Emerging trends and future directions

Didem Kaymak, Ayse Seval Ozgu-Erdinc

Specialty type: Endocrinology and metabolism

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification

Scientific Quality: Grade A, Grade A, Grade A, Grade B, Grade C

Novelty: Grade B, Grade B, Grade C

Creativity or Innovation: Grade B, Grade B, Grade C

Scientific Significance: Grade A, Grade A, Grade C

P-Reviewer: Horowitz M, MD, PhD, Professor, Australia; Huo WQ, PhD, Associate Professor, China; TokluBaloglu H, PhD, Assistant Professor, Türkiye; Wang P, Associate Professor, China

Received: June 27, 2025

Revised: July 14, 2025

Accepted: September 10, 2025

Published online: October 15, 2025

Processing time: 110 Days and 11.3 Hours

Didem Kaymak, Department of Perinatology, Istanbul Education and Research Hospital, Istanbul 34098, Türkiye

Ayse Seval Ozgu-Erdinc, Department of Perinatology, University of Health Sciences, Ankara Bilkent City Hospital, Ankara TR-06800, Türkiye

Corresponding author: Ayse Seval Ozgu-Erdinc, MD, Full Professor, Department of Perinatology, University of Health Sciences, Ankara Bilkent City Hospital, Üniversiteler Mahallesi 1604. Cadde No. 9 Bilkent/Çankaya, Ankara TR-06800, Türkiye.
sevalerdinc@gmail.com

Abstract

Gestational diabetes mellitus (GDM) is a multifactorial metabolic disorder first recognized during pregnancy, with rising global prevalence and significant implications for both maternal and neonatal outcomes. This review provides a comprehensive synthesis of current diagnostic strategies, including standard screening protocols such as the one-step and two-step oral glucose tolerance tests, and evaluates their limitations in terms of sensitivity, timing, and practicality. The complex pathogenesis of GDM-centered on β-cell dysfunction, insulin resistance, adipose tissue dysregulation, placental transport abnormalities, and neurohormonal imbalance-is explored in detail, highlighting the interplay of metabolic, inflammatory, and epigenetic mechanisms. Particular emphasis is placed on the emerging role of predictive biomarkers, encompassing metabolic, inflammatory, placental, urinary, and genetic indicators. These biomarkers, including adipokines, angiogenic factors, and microRNAs, offer promising avenues for early identification of at-risk individuals prior to the onset of hyperglycemia. The review also assesses recent advances in machine learning-based risk prediction models, which have demonstrated superior accuracy over traditional algorithms and may facilitate personalized screening and management strategies. Despite encouraging findings, challenges such as biomarker standardization, ethnic variability, and model validation persist. This review underscores the necessity for integrated, multi-omic, and patient-centered approaches to optimize GDM prediction, early diagnosis, and long-term risk reduction for both mother and child.

Key Words: Gestational diabetes mellitus; Predictive biomarkers; Insulin resistance; B-cell dysfunction; Machine learning; Early screening

©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This review offers an integrative and up-to-date overview of gestational diabetes mellitus (GDM), emphasizing the evolving understanding of its pathophysiology and the emerging role of multi-modal biomarkers in early prediction. By combining evidence on metabolic, inflammatory, placental, genetic, and urinary biomarkers, alongside advanced machine learning-based models, this work underscores the shift toward precision diagnostics. It critically evaluates conventional screening strategies and highlights avenues for improving early detection and individualized care. The synthesis aims to support clinicians and researchers in refining GDM risk stratification and mitigating long-term maternal-fetal consequences.

Citation: Kaymak D, Ozgu-Erdinc AS. Advances in gestational diabetes mellitus screening: Emerging trends and future directions. *World J Diabetes* 2025; 16(10): 111309
URL: https://www.wjgnet.com/1948-9358/full/v16/i10/111309.htm
DOI: https://dx.doi.org/10.4239/wjd.v16.i10.111309

INTRODUCTION

Gestational diabetes mellitus (GDM) is a transient yet clinically significant metabolic disorder first recognized during pregnancy, characterized by glucose intolerance leading to hyperglycemia[1]. The condition arises due to pancreatic β-cell dysfunction combined with increased insulin resistance, driven by hormonal changes during pregnancy[2]. Insulin resistance progressively worsens as gestation advances, often peaking in the third trimester, making early identification and intervention crucial[1]. Diabetes mellitus (DM) prevalence varies globally, ranging from 6% to 20%, influenced by ethnic, genetic, and environmental factors, with an increasing incidence due to the obesity epidemic and changing diagnostic criteria[3,4]. The incidence of GDM increases with the presence of risk factors common to type 2 diabetes, such as obesity and advanced maternal age. The risk factors are shown in Table 1[5]. Women diagnosed with GDM face significant maternal and neonatal risks, including preeclampsia, fetal macrosomia, neonatal hypoglycemia, and a heightened lifetime risk of type 2 DM (T2DM). Additionally, long-term consequences for offspring include childhood obesity and an increased risk of metabolic syndrome (Table 2)[6,7].

Standard screening for GDM typically involves an oral glucose tolerance test (OGTT) between 24 and 28 weeks of gestation, following a 50-g glucose challenge test (GCT) in some protocols. While both methods are widely accepted, regional and institutional preferences vary based on population risk profiles, accessibility, and healthcare system resources. However, limitations exist in both strategies, including suboptimal predictive capacity for early intervention, variability in patient adherence, and the inconvenience of prolonged fasting and glucose load administration[5,8]. Consequently, alternative biomarkers and technological innovations, such as machine learning (ML)-based risk assessment models, have been explored to refine early screening and diagnostic accuracy[9,10].

STANDART SCREENING METHODS FOR GDM

According to the American Diabetes Association (ADA) 2025 guidelines, the one-step 75-g OGTT is the preferred method, requiring a fasting glucose measurement, followed by 1-hour and 2-hour glucose readings[5]. The ADA defines GDM as present if any of the following thresholds are met: Fasting glucose: ≥ 92 mg/dL (5.1 mmol/L), 1-hour glucose: ≥ 180 mg/dL (10.0 mmol/L), 2-hour glucose: ≥ 153 mg/dL (8.5 mmol/L)[5]. Alternatively, the two-step approach, recommended by the American College of Obstetricians and Gynecologists (ACOG) 2018 guidelines, begins with a 50-g GCT (non-fasting). If the 1-hour plasma glucose level is ≥ 140 mg/dL (7.8 mmol/L), a 100-g OGTT is conducted after an overnight fast. GDM is diagnosed if at least two of the following criteria are met: Fasting glucose: ≥ 95 mg/dL (5.3 mmol/L), 1-hour glucose: ≥ 180 mg/dL (10.0 mmol/L), 2-hour glucose: ≥ 155 mg/dL (8.6 mmol/L), 3-hour glucose: ≥ 140 mg/dL (7.8 mmol/L) (Table 3)[8].

Screening during the preconception period is recommended for individuals at risk of diabetes or those belonging to high-risk populations[11-13]. Preconceptional screening facilitates the management of pre-existing diabetes, enabling the achievement of lower glycated hemoglobin (HbA1c) levels prior to pregnancy. This, in turn, has been associated with a reduced incidence of congenital anomalies, preterm birth, perinatal mortality, and neonatal intensive care unit admissions[8]. Among individuals with risk factors (Table 1) who have not undergone preconceptional screening, early universal screening before the 15th gestational week has been reported to be a more effective approach compared to selective screening[13-15]. In individuals diagnosed with GDM in early pregnancy, the risks of preeclampsia, macrosomia, shoulder dystocia, and perinatal mortality are increased, along with a higher likelihood of requiring insulin therapy[16-18]. Conversely, no significant association has been reported between adverse perinatal outcomes and HbA1c levels below 5.7%[19,20]. Although the effectiveness of treating abnormal glucose metabolism in early pregnancy remains inconclusive, it is recommended that patients receive nutritional counseling and undergo weekly periodic glucose monitoring. In particular, for individuals with fasting blood glucose levels of 110 mg/dL, intensive treatment and close follow-up should be initiated before the 18th gestational week[5]. While HbA1c is an inexpensive and widely accessible

Table 1 Risk factors for gestational diabetes mellitus

Risk factors
Overweight or obese adults (BMI ≥ 25 kg/m^2, ≥ 23 kg/m^2 for Asians) with at least one of the following risk factors:
History of diabetes in a first-degree relative
High-risk race or ethnicity (*e.g.*, African American, Latin American)
History of cardiovascular disease
HDL cholesterol level < 35 mg/dL (< 0.9 mmol/L) and/or triglyceride level > 250 mg/dL (> 2.8 mmol/L)
Polycystic ovary syndrome
Physical inactivity
Other clinical conditions associated with insulin resistance (obesity, acanthosis nigricans)
Prediabetes (HbA1c ≥ 5.7%) and impaired fasting and glucose tolerance
Individuals previously diagnosed with GDM
Individuals afflicted with HIV, those utilizing medications that elevate the risk of diabetes, and those with a history of pancreatitis. Additionally, ACOG:
History of birth over 4000 g
Hypertension (140/90 mmHg or those taking antihypertensive medication)

Risk factors for gestational diabetes mellitus[5]. BMI: Body mass index; HDL: High density lipoprotein; GDM: Gestational diabetes mellitus; ACOG: American College of Obstetricians and Gynecologists; HIV: Human immunodeficiency virus; HbA1c: Glycated hemoglobin.

Table 2 Maternal and fetal complications of gestational diabetes mellitus

	Maternal	Fetal
Short term	Preeclampsia	Macrosomia
	Preterm delivery	Shoulder dystocia
	Caesarean section	Perinatal mortality
	Failure to progress in labour and instrumental delivery	Admission to NICU
		Neonatal hypoglycaemia
		Hyperbilirubinaemia
Long term	Recurrent GDM in subsequent pregnancies	Type 2 diabetes
	Type 2 diabetes	Obesity
	Cardiovascular disease	

Maternal and fetal complications of gestational diabetes mellitus[6,7]. GDM: Gestational diabetes mellitus; NICU: Neonatal intensive care unit.

test, it has been reported to be insufficient in distinguishing between pregestational diabetes and GDM when screening is conducted after the 15th gestational week.

The large-scale, multinational Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study, which included more than 23000 pregnant individuals, demonstrated a linear relationship between increasing maternal glycemic levels at 24-28 weeks of gestation and adverse maternal, fetal, and neonatal outcomes. Moreover, the study identified an increased risk of adverse outcomes even within glycemic ranges previously considered normal for pregnancy[21]. The International Association of Diabetes and Pregnancy Study Groups, based on the findings of the HAPO study, established diagnostic threshold values for GDM using the one-step 75 g OGTT conducted at 24-28 weeks of gestation. Analysis of adverse pregnancy outcomes demonstrated a 1.75-fold increased risk in individuals diagnosed with GDM. The adoption of these criteria is projected to increase the prevalence of GDM from 5%-6% to 15%-20%, raising concerns regarding additional healthcare costs and the potential medicalization of pregnancies previously considered normal[22]. Long-term follow-up studies have shown that individuals diagnosed with GDM have a 3.4-fold increased risk of developing prediabetes and T2DM postpartum. Furthermore, their offspring exhibit an increased risk of obesity and metabolic disorders.

The GDM screening strategies recommended by ADA, ACOG, the World Health Organization, the International Federation of Gynecology and Obstetrics, and the National Institute for Health and Care Excellence are presented in Table 4[5,8,23,24].

Table 3 Screening and diagnosis of gestational diabetes mellitus

	One-step strategy	Two-step strategy
Test	75 g OGTT: In individuals without a prior diagnosis of diabetes, screening is performed in the fasting state between 24 and 28 weeks of gestation (following a minimum of 8 hours of overnight fasting). GDM is diagnosed if any of the following blood glucose thresholds are met or exceeded	First step: 50 g glucose challenge test: This test is administered between 24 and 28 weeks of gestation in individuals without a prior diagnosis of diabetes and does not require fasting. If the 1-hour plasma glucose level meets or exceeds the specified threshold values, a 100 g OGTT should be performed
Blood glucose thresholds	IADPSG: Fasting glucose ≥ 93 mg/dL (≥ 5.1 mmol/L)	Fasting glucose ≥ 95 mg/dL (≥ 5.3 mmol/L)
	1-hour plasma glucose ≥ 180 mg/dL (≥ 10.0 mmol/L)	1-hour plasma glucose ≥ 180 mg/dL (≥ 10.0 mmol/L)
	2-hour plasma glucose ≥ 153 mg/dL (≥ 8.5 mmol/L)	2-hour plasma glucose ≥ 155 mg/dL (≥ 8.6 mmol/L)
	Carpenter-Coustan criteria: Fasting glucose ≥ 95 mg/dL (≥ 5.3 mmol/L)	2-hour plasma glucose ≥ 140 mg/dL (≥ 7.8 mmol/L)
	1-hour plasma glucose ≥ 180 mg/dL (≥ 10.0 mmol/L)	
	2-hour plasma glucose ≥ 155 mg/dL (≥ 8.6 mmol/L)	

Screening and diagnosis of gestational diabetes mellitus[8]. IADPSG: International Association of Diabetes and Pregnancy Study Groups; OGTT: Oral glucose tolerance test; GDM: Gestational diabetes mellitus.

Table 4 Gestational diabetes mellitus screening strategies recommended by various international organizations

Guide	Strategy
ADA	75 g OGTT for all pregnant women
ACOG	Administer a 50 g GCT for all pregnant women; a 100 g OGTT is required if the initial test is positive
WHO	75 g OGTT for all pregnant women
NICE	75 g OGTT risk-based approach
FIGO	75 g OGTT for all pregnant women

Gestational diabetes mellitus screening strategies recommended by various international organizations[5,8,23,24]. ACOG: American College of Obstetricians and Gynecologists; NICE: National Institute for Health and Care Excellence; FIGO: International Federation of Gynecology and Obstetrics; WHO: World Health Organization; ADA: American Diabetes Association; OGTT: Oral glucose tolerance test; GCT: Glucose challenge test.

PATHOGENESIS OF GDM

The two primary factors contributing to the development of GDM are β-cell dysfunction and insulin resistance. In most cases, these abnormalities preexist before pregnancy, may progress during gestation, and explain the increased risk of T2DM in the postpartum period (Figure 1).

The primary function of β-cells is to synthesize, store, and secrete insulin in response to glucose load. When there is a failure in glucose sensing or insulin secretion, this condition is defined as β-cell dysfunction. It has been proposed that chronic energy excess leads to prolonged and excessive insulin production in β-cells, causing functional impairment[2]. However, the pathophysiology of β-cell dysfunction is complex and involves multiple mechanisms[25,26]. Dysfunction may occur at various stages, including proinsulin synthesis, post-translational modifications, insulin granule storage, glucose-sensing mechanisms, or insulin granule exocytosis. The potassium voltage-gated channel *KCNQ1* and *GCK* genes play crucial roles in the regulation of β-cell function. The literature indicates that most genetic variants associated with GDM are linked to β-cell function-related genes. Additionally, minor defects in β-cell mechanisms may become evident under metabolic stress conditions such as pregnancy, contributing to GDM development[26]. β-cell dysfunction is further exacerbated by insulin resistance, leading to reduced glucose uptake and increased β-cell workload, which in turn contributes to hyperglycemia. The direct impact of glucose on β-cell failure is termed glucotoxicity[27]. This process establishes a vicious cycle between hyperglycemia, insulin resistance, and β-cell dysfunction. Over time, glucotoxicity triggers β-cell apoptosis, resulting in a decline in pancreatic β-cell mass. In patients with T2DM, β-cell mass reduction of approximately 40%-60% has been reported, and this loss becomes more pronounced as the disease progresses[28,29]. Based on existing animal and human studies, it has been proposed that a combination of β-cell mass reduction, functional impairment, and inadequate insulin secretion contributes to the development of GDM[30].

Insulin resistance occurs when cells fail to respond effectively to insulin and is primarily associated with disruptions in insulin signaling pathways. In GDM, glucose uptake is impaired due to a reduction in GLUT4 translocation to the plasma membrane, with a reported 54% decrease compared to normal pregnancy[31]. While insulin receptor expression remains intact, a reduction in tyrosine phosphorylation of the receptor disrupts insulin signaling and decreases insulin sensitivity



Figure 1 Pathogenesis of gestational diabetes mellitus. TNF: Tumor necrosis factor; IGF-1: Insulin-like growth factor 1; HPL: Human placental lactogen; hPFG: Human placental growth hormone; IGF1: Insulin-like growth factor 1; IGFBP3: Insulin-like growth factor binding protein 3.

[32]. Additionally, alterations in the expression and phosphorylation of key insulin signaling regulators such as IRS-1, PI3K, and GLUT4 have been observed[14]. Many of these molecular changes persist postpartum[33].

Neurohormonal dysfunction also plays a role in GDM pathogenesis. This complex network regulates appetite, energy expenditure, and basal metabolic rate through central (*e.g.*, cortical centers controlling cognitive, visual, and "reward" cues) and peripheral (*e.g.*, satiety and fasting hormones) signals. Dysregulation of this network contributes to GDM by affecting adiposity and glucose utilization. This system is largely governed by circadian rhythms, explaining the association between GDM and pathological sleep disorders or shift work. The most well-known hormones involved are leptin and adiponectin. Leptin, secreted by adipocytes and the placenta, regulates energy homeostasis. Leptin levels are elevated in GDM, and hyperleptinemia has been associated with placental insulin resistance. Increased leptin levels have been reported to enhance fetal amino acid transport *via* the placenta, contributing to fetal macrosomia[34]. Furthermore, leptin resistance has been reported in GDM pregnancies, impairing leptin signaling in peripheral tissues and negatively affecting glucose homeostasis[35]. Conversely, adiponectin, a hormone that enhances insulin sensitivity and suppresses gluconeogenesis, is significantly reduced in GDM. This reduction is linked to β-cell dysfunction and insulin resistance [36]. Moreover, decreased placental adiponectin expression has been suggested to contribute to fetal growth restriction, potentially counteracting the risk of macrosomia[37]. Lower adiponectin levels correlate with maternal glucose intolerance, suggesting a pivotal role for this hormone in GDM pathogenesis[38].

Another key factor in GDM pathogenesis is altered adipose tissue storage. While early pregnancy is characterized by adipose tissue expansion, later gestation involves increased lipid mobilization to support fetal growth. These adipose tissue-related adaptations appear to become dysregulated in the context of GDM[39]. The condition is characterized by impaired adipogenesis and exaggerated adipocyte hypertrophy, alongside suppression of critical components of the insulin signaling cascade, including transcription factors such as PPARγ, as well as fatty acid transport proteins[40]. The resulting decline in insulin sensitivity, coupled with defective adipocyte maturation, compromises the adipose tissue's capacity for efficient energy storage. This maladaptation promotes ectopic lipid deposition and exacerbates glucolipotoxicity in peripheral tissues, notably skeletal muscle and hepatic parenchyma, a feature shared with T2DM.

The placenta plays a crucial role in modulating insulin resistance during pregnancy by secreting hormones and cytokines[41]. In GDM, the hyperglycemic intrauterine environment affects the transport of glucose, amino acids, and lipids across the placenta. Glucose transport across the placenta is insulin-independent, but maternal hyperglycemia significantly influences this process, directly contributing to increased fetal growth and macrosomia[42]. Similarly, alterations in system A and L amino acid transporters affect fetal growth[43]. Additionally, most placental gene expression changes in GDM occur in lipid pathways, influencing glucose transport[44].

GDM has been reported to induce widespread hypermethylation in the placenta, triggering epigenetic modifications. However, the exact role of placental epigenetic and proteomic alterations remains unclear[45]. Other factors implicated in GDM pathogenesis include gut microbiota, oxidative stress, and environmental toxin exposure.

BIOMARKERS AS PREDICTION TOOLS FOR DETERMINING GDM

Biomarkers are measurable biological substances that serve as indicators of normal physiological processes, pathological mechanisms, or pharmacodynamic responses to therapeutic interventions[46]. They can be categorized as predictive markers, which evaluate the likelihood of disease development, or as diagnostic and screening tools that facilitate early detection during the subclinical phase, enabling timely intervention to prevent disease progression or anticipate treatment outcomes. Recent research has focused on biomarker-based approaches for improving the early detection of GDM. Various metabolic, inflammatory, and placental-derived biomarkers have shown promise in predicting GDM risk before hyperglycemia becomes clinically evident[47] (Figure 2).

Metabolic biomarkers

Given the established dysregulation of glucose metabolism in GDM, various metabolic markers have been explored to predict its onset. Elevated insulin resistance indices during the first trimester, assessed *via* the homeostasis model assessment of insulin resistance (HOMA-IR) using fasting serum glucose and insulin levels, have been linked to a heightened risk of developing GDM[48]. A study demonstrated that increased HOMA-IR in early pregnancy is a significant risk factor for GDM, with specific cutoff values varying based on body weight categories[49]. However, insulin resistance alone may be insufficient as a predictive marker, as not all studies conclusively demonstrate this association.

Pregnancy naturally involves a progressive decline in insulin sensitivity, accompanied by increased insulin resistance, peaking in the third trimester and diminishing postpartum[32]. Early gestational assessments of insulin sensitivity, employing indices such as the Matsuda index (derived from OGTT), quantitative insulin sensitivity check index, and HOMA for sensitivity, have been investigated as potential predictors of GDM[49]. Given that alterations in insulin sensitivity precede GDM manifestation, further validation of these measures could facilitate early interventions before GDM develops[9].

Sex hormone-binding globulin (SHBG), a glycoprotein that binds androgens and estrogens, has been implicated in glucose metabolism and the development of type 2 diabetes[50]. Low levels of SHBG are associated with insulin resistance and the development of GDM[51]. However, the predictive significance of SHBG diminishes when adjusting for factors such as body mass index (BMI), ethnicity, and family history, underscoring the necessity for biomarkers that offer predictive value beyond standard clinical risk factors[9].

Lipid metabolism undergoes significant changes during pregnancy, with the first and second trimesters marking substantial maternal fat accumulation due to increased lipid synthesis[52]. Lipid levels rise progressively, peaking in late gestation[53]. Triglycerides do not directly cross the placenta; however, placental lipoprotein receptors facilitate fatty acid transfer along the maternal-fetal gradient. In GDM, these alterations are more pronounced, with elevated triglyceride levels observed across all trimesters[54]. Elevated maternal triglycerides in the third trimester are positively correlated with increased fetal birth weight, independent of GDM status[55]. Conversely, higher maternal high-density lipoprotein (HDL) levels are inversely associated with the risk of fetal macrosomia[56]. While the association between disrupted maternal lipid profiles and GDM is established, their utility as predictive biomarkers requires further elucidation.

Given that GDM is a metabolic disorder, multiple studies have investigated metal ions, lipidomics, amino acids, metabolites, and vitamins as potential predictive biomarkers. Among metal ions evaluated in early pregnancy, iron and selenium demonstrated significantly different levels between GDM and normoglycemic pregnancies, with a sensitivity exceeding 80%[57]. Elevated iron levels contribute to oxidative stress by increasing reactive oxygen species[58] production, whereas selenium, as a cofactor for antioxidant enzymes, supports placental function, and its deficiency may be linked to GDM development. The involvement of these redox-sensitive elements suggests a potential role for oxidative stress in GDM pathogenesis, likely associated with placental and mitochondrial dysfunction[57].

Nutritional status is crucial for maternal and fetal health. Lower vitamin D (25-hydroxyvitamin D) levels in the first trimester were associated with 81% sensitivity but only 44% specificity for GDM prediction, while elevated vitamin A levels in early pregnancy exhibited moderate predictive value [area under the curve (AUC) = 0.649]. Both vitamins A and D are implicated in immune regulation and insulin sensitivity, and their deficiency may contribute to GDM pathophysiology[59]. Metabolomic profiling has identified several biomarkers for GDM prediction, with branched-chain amino acids (BCAAs)-valine, isoleucine, and leucine-demonstrating predictive values ≥ AUC 0.67 and a sensitivity exceeding 76%. Since BCAAs are linked to energy metabolism, their elevated levels correlate with insulin resistance and metabolic dysfunction, both central to GDM development[60].

Inflammatory biomarkers

Obesity is a well-established risk factor for GDM, characterized by a state of chronic low-grade inflammation due to excessive nutrient and energy intake[9]. This pro-inflammatory state disrupts metabolic pathways in adipose tissue, the liver, and pancreas, altering levels of adipokines, chemokines, and cytokines[61,62]. Among these, tumor necrosis factor-alpha (TNF-α), secreted by the placenta, has been implicated in pregnancy-induced insulin resistance. A case-control study demonstrated that elevated maternal TNF-α levels at 11-13 weeks of gestation were associated with increased GDM risk[63]. Similarly, C-reactive protein (CRP), an inflammatory marker, has been investigated as a potential predictor of GDM, though its association weakens after BMI adjustment, limiting its specificity[64,65]. Interleukin-6 (IL-6), predominantly derived from adipocytes, is positively correlated with adiposity measures and insulin resistance[9]. Even in the absence of maternal obesity, higher circulating IL-6 Levels have been linked to GDM development. However, its role as a pro-spective predictor of GDM remains uncertain, as studies have yet to establish whether its elevation precedes the onset of GDM or simply reflects its pathophysiology[66].



Figure 2 Biomarkers in gestational diabetes mellitus. CRP: C-reactive protein; MHR: Monocyte-to-high-density lipoprotein ratio; SII: Systematic immune inflammation index; SIRI: Systemic inflammation response index; PAPPA-2: Pregnancy-associated plasma protein-A2; PP13: Placental protein 13; FABP4: Fatty acid-binding protein 4; SNP: Single nucleotide polymorphisms; miRNA: MicroRNAs; BCAAs: Branched-chain amino acids; sFlt-1: Soluble fms-like tyrosine kinase-1; SHBG: Sex hormone-binding globulin.

This large-scale retrospective study, involving 15807 pregnant women, investigated the association between systemic inflammatory markers in early pregnancy and the risk of developing GDM. The findings revealed that women diagnosed with GDM exhibited lower monocyte counts and higher neutrophil and lymphocyte counts compared to the non-GDM group. Notably, monocyte count and monocyte-to-high-density lipoprotein ratio (MHR) were significantly associated with GDM risk, with a lower monocyte count and MHR correlating with an increased likelihood of GDM development. However, other inflammatory indices, including systematic immune inflammation index and systemic inflammation response index, did not show a strong predictive value. Subgroup analysis further suggested that the association between monocyte count/MHR and GDM risk was particularly pronounced in women with a family history of diabetes. These findings propose that readily accessible inflammatory markers could serve as potential early indicators of GDM risk, highlighting the need for further validation in larger, multi-ethnic cohorts to establish their clinical utility in early GDM screening and prevention strategies[67].

Adipokine profiles in GDM pregnancies differ significantly from those in normoglycemic pregnancies, with decreased adiponectin and nesfatin-1 Levels, and increased leptin, resistin, visfatin, vaspin, and spexin[68]. The predictive performance of adipokines and cytokines varies widely, with AUC values ranging from 0.337 to 0.836, though 10 biomarkers exhibit an AUC > 0.7, indicating moderate predictive potential[68,69]. Among these, leptin and adiponectin are the most promising biomarkers, demonstrating 100% sensitivity in small cohort studies[70]. Leptin, which regulates energy homeostasis and insulin sensitivity, is elevated in GDM, likely reflecting increased adiposity and insulin resistance. In contrast, adiponectin, which enhances insulin sensitivity, is significantly reduced, suggesting impaired glucose metabolism in GDM[71].

Placental biomarkers

The placenta plays a pivotal role in inflammatory regulation, with its contribution becoming more pronounced in obesity, where it serves as a significant source of pro-inflammatory cytokines, including IL-1, TNF-α, and IL-6[9]. Although the placenta has adaptive mechanisms to protect the fetus from inflammation , alterations in glucose transport have been observed, primarily mediated through modulation of glucose transporters (GLUTs)[72]. In GDM pregnancies, placental GLUT9a expression is markedly increased, a phenomenon further exacerbated by exposure to exogenous insulin[73]. Conversely, GLUT1 expression in the basal membrane remains stable within physiological glucose concentrations but is altered under extreme glycemic conditions[74]. Despite these compensatory mechanisms, placental glucose uptake in GDM is elevated by 2-3-fold, reflecting a substantial adaptation to maternal metabolic disturbances[75]. This evidence highlights the critical regulatory role of the placenta in modulating the fetal environment, attempting to mitigate the impact of maternal metabolic dysfunction at a cellular level. A deeper understanding of placental physiology may facilitate the identification of novel biomarkers for GDM and its associated fetal complications[9].

Placental dysfunction can disrupt the secretion of placental hormones, leading to an imbalance between pregnancy-induced insulin secretion and insulin resistance, thereby contributing to GDM development[76]. Several placenta-derived proteins have shown predictive potential for GDM[77]. Pregnancy-associated plasma protein-A2 (PAPP-A2), measured at approximately 13.6 weeks of gestation, and placental protein 13 (PP13), assessed between 16-20 weeks, demonstrated sensitivities of 71% and 92%, respectively[78]. PAPP-A2 regulates insulin-like growth factor activity, which is essential for fetal growth and glucose metabolism; its elevated levels may indicate placental stress or dysfunction, contributing to GDM onset[58]. Similarly, PP13 is involved in placental development and vascularization, and altered levels may signal impaired placental function, predisposing to GDM[10]. Emerging evidence supports the clinical utility of PAPP-A2 as a promising early biomarker for GDM. In a case-control study by Dereke *et al*[78], circulating PAPP-A2 Levels were significantly elevated in women diagnosed with early-pregnancy GDM compared to matched normoglycemic controls (median 13.5 ng/mL *vs* 8.1 ng/mL; $P < 0.001$). Importantly, PAPP-A2 Levels were independently associated with GDM after adjusting for age, BMI, C-peptide, and adiponectin. At a cut-off value of 6 ng/mL, the marker demonstrated a sensitivity of 96% and a negative predictive value of 99.7%, indicating strong potential for early risk stratification and reduction in unnecessary OGTTs. While these findings position PAPP-A2 as a compelling candidate for pre-screening, larger prospective cohorts are warranted to validate its performance across diverse populations[78].

Additionally, angiogenic factors, such as prokineticin 1 and soluble fms-like tyrosine kinase-1 (sFlt-1), have demonstrated strong predictive accuracy for GDM in the early second trimester, with sensitivities of 88% and 95%, respectively[10,79]. Prokineticin 1 plays a role in angiogenesis and placental function, and its dysregulation may impair placental blood flow and nutrient exchange, increasing GDM risk[79]. sFlt-1, an antiangiogenic factor, disrupts placental vascularization, contributing to placental insufficiency and metabolic dysfunction[10]. In contrast, placental growth factor, a key biomarker for preeclampsia, has shown limited utility in predicting GDM, with a sensitivity of only 51%, suggesting it is not a reliable standalone predictor[80].

Afamin is a vitamin-E-binding glycoprotein, exhibited elevated concentrations in early pregnancy among GDM cases, reinforcing its link to oxidative stress and metabolic dysfunction[81]. Fatty acid-binding protein 4 (FABP4), galectin-3 (Gal-3), and fibronectin were also identified as potential markers, with higher FABP4 and Gal-3 Levels correlating with GDM onset, while fibronectin levels were lower in affected individuals[82-84]. Furthermore, CD93 and HTRA-1, both implicated in angiogenesis and placental remodeling, showed altered expression in GDM, suggesting their involvement in disease pathogenesis[85,86]. Although these findings underscore the potential of biomarker-based GDM prediction, variability across studies, limited cohort sizes, and the influence of ethnic, environmental, and metabolic factors necessitate further large-scale, multi-ethnic validation studies to establish their clinical applicability.

Genetic and epigenetic biomarkers

Genetic predisposition plays a significant role in the pathogenesis of GDM, with numerous single nucleotide polymorphisms (SNPs) identified in genes related to insulin secretion, glucose metabolism, and adipose tissue function[87]. The *TCF7 L2* gene, a key regulator in the Wnt signaling pathway, has been strongly associated with both type T2DM and GDM. Among the most frequently studied polymorphisms, rs7903146 and rs4506565 have been linked to an increased risk of GDM, with individuals carrying the T allele of rs7903146 demonstrating higher proinsulin-to-insulin ratios, impaired insulinotropic effects of incretin hormones, and greater hepatic glucose production[88,89]. Similarly, MTNR1B, which encodes the melatonin receptor 1B, has been implicated in glucose intolerance and insulin resistance. The rs10830963 SNP in MTNR1B is frequently associated with elevated fasting glucose, increased HbA1c levels, and reduced early-phase insulin secretion, potentially modifying the effectiveness of lifestyle interventions in high-risk populations[90,91]. Additionally, *ADIPOQ*, a gene encoding adiponectin, has been linked to GDM risk through SNPs such as rs2241766, where the G allele is associated with reduced adiponectin levels and increased insulin resistance[92].

Beyond genetic predisposition, epigenetic modifications, particularly microRNAs (miRNAs), have emerged as crucial regulators in GDM development and progression. miRNAs are short non-coding RNAs that modulate gene expression post-transcriptionally, influencing β-cell function, insulin sensitivity, and inflammatory responses. Several miRNAs, including miR-29a, miR-29b, miR-132, and miR-223, have been differentially expressed in GDM pregnancies[93]. Notably, miR-29a downregulation has been linked to impaired glucose metabolism through its role in regulating phosphoenolpyruvate carboxykinase 2, a key enzyme in gluconeogenesis[94]. Moreover, miR-657 has been implicated in macrophage-mediated inflammation, promoting a pro-inflammatory environment that may contribute to GDM pathogenesis. Importantly, miRNA dysregulation appears to precede glucose abnormalities, suggesting their potential utility as early biomarkers for GDM diagnosis[95].

Further supporting the role of epigenetics, trimester-specific miRNA expression patterns have been observed in GDM pregnancies. Studies indicate that miR-517-3p and miR-518-5p exhibit increased levels in the second trimester, whereas their expression is downregulated in the third trimester, potentially reflecting dynamic regulatory mechanisms in placental function and maternal metabolic adaptation[96]. Similarly, miR-125b-5p is upregulated in the first trimester but declines in the second trimester, highlighting the need for longitudinal studies to characterize miRNA fluctuations throughout pregnancy[97]. The clinical utility of circulating miRNAs as predictive biomarkers for GDM has been supported by cohort-based validation studies. In a prospective analysis by Juchnicka *et al*[98], serum samples from the first trimester were evaluated in 48 pregnant women, including 24 who later developed GDM and 24 normoglycemic controls. Using NanoString-based profiling followed by RT-PCR validation, the study identified three significantly upregulated miRNAs-miR-16-5p, miR-142-3p, and miR-144-3p-in the GDM group. ROC curve analysis demonstrated strong diagnostic performance, with AUC values of 0.868, 0.778, and 0.756, respectively. These findings reinforce the potential of microRNA panels for early, non-invasive GDM screening, and suggest that first-trimester expression signatures may precede clinical glycemic alterations[98]. Further supporting the utility of circulating miRNAs in early GDM prediction, Ye *et al*[99] identified a plasma exosomal miRNA panel-miR-122-5p, miR-148a-3p, miR-192-5p, and miR-

99a-5p-that demonstrated robust discriminatory power in a nested case-control study conducted between 10 and 16 gestational weeks (AUC = 0.82). These miRNAs were significantly dysregulated in women who subsequently developed GDM and were mechanistically linked to insulin and AMPK signaling pathways. This study provides compelling evidence supporting the feasibility of non-invasive, early screening strategies based on extracellular vesicle-derived miRNAs[99].

These findings underscore the complex interplay between genetic susceptibility and epigenetic modifications in GDM, paving the way for biomarker-based risk stratification and personalized interventions. However, large-scale multi-ethnic cohort studies are required to validate these findings and establish standardized biomarker panels for clinical use.

Urine biomarkers

Recent advances in metabolomics and proteomics have facilitated the identification of potential urinary biomarkers for early prediction and diagnosis of GDM. Given its non-invasive collection and ability to reflect metabolic changes, urine has emerged as a promising biofluid for biomarker discovery[100]. Studies have demonstrated significant alterations in amino acid metabolism, particularly BCAAs and tryptophan metabolites, in women who later develop GDM[101]. Elevated urinary serotonin, kynurenine, and indole metabolites suggest dysregulation in the tryptophan-kynurenine pathway, which may contribute to IR and β-cell dysfunction[102]. Similarly, increased purine metabolites such as hypoxanthine, xanthine, and uric acid have been linked to oxidative stress and chronic inflammation, key factors in GDM pathogenesis[103]. Lipid metabolites, including ceramides, sphingomyelins, and glycerophospholipids, have also been identified as potential markers, reflecting dysregulated lipid metabolism and insulin signaling[104].

In addition to metabolomic changes, proteomic analyses have revealed several proteins with potential diagnostic value for GDM. Liver-type fatty acid-binding protein, a marker of renal stress and lipid metabolism, is significantly elevated in GDM patients, suggesting a role in early metabolic disturbances[105]. Similarly, inter-alpha-trypsin inhibitor heavy chain H4, an acute-phase inflammatory protein, has been correlated with hyperglycemia severity and adverse neonatal outcomes[106]. Moreover, coagulation factor IX and other fibrinolysis-related peptides were found to be upregulated in GDM, reflecting the pro-thrombotic state associated with hyperglycemia. These findings highlight the potential clinical utility of urinary biomarkers in identifying at-risk women before traditional diagnostic criteria are met, offering a window for early intervention[106].

Despite these promising discoveries, heterogeneity in findings, lack of large-scale validation, and inconsistencies due to diet, ethnicity, and analytical techniques remain key challenges. Future research should focus on standardized protocols for biomarker validation, longitudinal studies tracking urinary changes throughout pregnancy, and multi-omics integration to enhance predictive accuracy. Ultimately, the incorporation of urinary biomarkers into routine screening strategies could improve risk stratification, facilitate early therapeutic interventions, and mitigate the long-term metabolic consequences of GDM[100].

When comparing the predictive performance of microRNA biomarkers with other biomarker categories discussed in this review, miRNAs generally demonstrate superior discriminative ability. For instance, first-trimester circulating miRNAs such as miR-16-5p, miR-142-3p, and miR-144-3p achieved AUC values of 0.868, 0.778, and 0.756, respectively, while a plasma exosomal miRNA panel reported yielded an AUC of 0.82[98,99]. These values exceed those observed for several metabolic and inflammatory markers. For example, BCAAs demonstrated moderate predictive performance (AUC around 0.67), adipokines showed highly variable results across studies (AUC range approximately 0.34-0.83), and vitamin D deficiency was linked to good sensitivity (approximately 81%) but limited specificity (approximately 44%)[60]. Inflammatory markers such as CRP and IL-6 have shown inconsistent associations and limited specificity after BMI adjustment[64,66]. Collectively, these findings suggest that miRNAs may offer more robust and consistent predictive power for early GDM detection compared to many single metabolic or inflammatory biomarkers, although direct head-to-head validation in large, multi-ethnic cohorts remains necessary.

ML-BASED PREDICTIONS FOR GDM

A recent meta-analysis including 25 studies demonstrated that ML-based models for GDM prediction achieved strong overall discriminatory performance. Notably, advanced algorithms such as decision trees, support vector machines, and neural networks consistently outperformed traditional logistic regression approaches, highlighting their promise for early risk stratification. Key predictors consistently identified across studies included maternal age, BMI, family history of diabetes, and fasting blood glucose levels, with additional emerging predictors such as triglycerides, PAPP-A, and leptin levels[107].

The analysis highlighted that early pregnancy ML models (0-13 weeks gestation) achieved the highest sensitivity (0.74), while models trained on data from 14-28 weeks gestation exhibited greater specificity (0.85), suggesting that ML-based tools may facilitate both early risk stratification and mid-gestation confirmatory screening. Notably, ensemble methods such as LightGBM and GA-CatBoost yielded superior predictive performance compared to DT and k-nearest neighbors, which struggled with high-dimensional clinical datasets. The study further emphasized that feature selection and data preprocessing are critical in optimizing ML model performance. While external validation was performed in only 16% of included studies, findings underscore the need for standardized diagnostic criteria, prospective validation, and real-world implementation studies to enhance clinical applicability[107].

Recent research has demonstrated the growing potential of machine learning ML models to identify women at high risk of GDM using early pregnancy data. Zaky *et al*[108] developed a stacked ensemble model incorporating 26 variables, including HOMA-IR, insulin, and NT-proBNP levels, from the Qatar Birth Cohort. Their model achieved a recall of 92.1%

and an accuracy of 88.8%, illustrating the feasibility of early, non-invasive GDM prediction[108]. Similarly, Kaya *et al*[109] retrospectively analyzed data from a Turkish tertiary center, using maternal sociodemographic and obstetric variables collected during the first trimester. Among multiple algorithms tested, the XGBoost classifier demonstrated the best performance, with accuracies of 66.7% and 72.7% and AUCs of 55% and 73.3% in nulliparous and primiparous subgroups, respectively[109]. Both studies highlighted key predictive features such as fasting plasma glucose, BMI, and family history of diabetes. A comparison of the AUC values from these two studies is presented in Figure 3, illustrating the relative performance of their ML models for GDM prediction. Despite promising results, challenges such as limited sample size, lack of external validation, and variability in electronic health records remain barriers to clinical translation. These examples underscore the need for standardized data pipelines, population-specific models, and prospective multicenter validation before ML tools can be effectively integrated into GDM screening protocols. Moreover, the real-world applicability of such models is contingent upon the availability of adequate computational infrastructure, which may be limited in low-resource settings. Tailoring ML tools for practical deployment in diverse clinical environments remains a critical step toward equitable implementation.

Recent advances in ML for GDM prediction demonstrate variable performance across different populations, underscoring the necessity of population-specific approaches to enhance predictive accuracy. In Chinese cohorts, the application of advanced algorithms such as deep neural networks and XGBoost has achieved robust discriminative capacity, with AUC values approaching 0.80, largely driven by the incorporation of context-specific predictors such as fasting plasma glucose and maternal age[110,111]. Similarly, in South Korean populations, the use of light gradient boosting machine and XGBoost has highlighted the importance of integrating both demographic and clinical variables from early pregnancy, thereby reinforcing the utility of tailored models at different gestational stages[112]. In ethnically diverse populations, CatBoost and related ML models have demonstrated strong performance with AUCs ranging from 71% to 93%, particularly when including key determinants such as GDM history, BMI, and ethnicity, further emphasizing the critical role of adapting predictors to population heterogeneity[113]. Collectively, these findings indicate that non-logistic ML algorithms consistently outperform traditional regression-based approaches, as supported by meta-analyses showing the recurrent predictive value of maternal age, BMI, and fasting glucose across cohorts[107]. Thus, the integration of population-specific risk factors into ML-based prediction frameworks represents a promising strategy for improving early identification and risk stratification of GDM in diverse clinical settings.

Despite the demonstrated potential of ML in improving GDM prediction, challenges remain. Heterogeneity among studies, differences in population characteristics, and inconsistencies in diagnostic criteria limit the generalizability of findings. Furthermore, the integration of ML models into clinical workflows necessitates robust validation, regulatory approval, and physician interpretability. Future research should focus on incorporating multi-omics data, wearable technology-derived biomarkers, and explainable AI approaches to further refine risk prediction and support personalized prenatal care strategies[107].

ML-based predictions for GDM progression to T2DM

The application of ML algorithms in predicting the progression from GDM to T2DM has gained increasing attention due to its potential for early risk stratification and personalized intervention[114]. Recent meta-analysis evaluated 13 studies involving 11320 women with a history of GDM, assessing the predictive accuracy of 22 ML models. The findings demonstrated that ML models achieved a pooled C-statistic of 0.82 (95%CI: 0.79-0.86), indicating strong discriminative ability for identifying women at high risk of developing T2DM. The pooled sensitivity (76%) was considerably higher than traditional risk assessment tools, though specificity remained moderate at 57%, highlighting the need for refinement in predictive models[114].

Different ML algorithms, including logistic regression, decision trees, random forest, Naïve Bayes, and Cox models, have been compared, with ensemble-based methods such as random forest generally demonstrating higher predictive accuracy than traditional regression approaches. Key predictive variables incorporated in these models included maternal metabolic markers, glucose and lipid metabolites, genetic factors, and traditional clinical risk factors. Notably, the inclusion of circulating miRNAs such as miR-369-3p and miR-543 significantly enhanced model performance by improving early risk assessment[114].

Despite promising results, several challenges remain in the clinical translation of ML models. The heterogeneity of study designs, variability in follow-up durations, and inconsistent validation protocols introduce potential bias and limit generalizability. Moreover, the lack of external validation in most models raises concerns regarding their real-world applicability across diverse populations[114]. Future research should prioritize large-scale prospective studies, integration of multi-omics data, and development of standardized ML algorithms to refine risk prediction and enhance clinical decision-making for postpartum women with a history of GDM. Ultimately, the incorporation of ML-based predictive models into clinical workflows could facilitate targeted interventions, reduce the burden of T2DM, and improve long-term maternal metabolic health outcomes.

CONCLUSION

Extensive research into the molecular pathogenesis of GDM has led to the identification of a broad spectrum of biomarkers with potential utility for early prediction and diagnosis. These include metabolic indices such as HOMA-IR and SHBG, lipid profiles, adipokines like leptin and adiponectin, placental proteins including PAPP-A2 and PP13, angiogenic factors such as sFlt-1 and prokineticin 1, as well as a range of miRNAs and urinary metabolites. Many of these markers exhibit significant correlations with insulin resistance, β-cell dysfunction, or placental insufficiency, all of which



Figure 3 Comparative area under the curve values of machine learning models in gestational diabetes mellitus prediction[108,109].
Created by the area under the curve values, prepared in Excel format.

contribute to GDM development. Although several candidates have shown moderate-to-high sensitivity and specificity in small- to medium-scale studies, clinical translation remains limited due to heterogeneity in study populations, biomarker variability across gestational ages, and lack of standardized thresholds. Nonetheless, the incorporation of validated biomarker panels into existing screening protocols may improve early risk stratification and allow for timely intervention prior to the clinical onset of hyperglycemia.

Simultaneously, ML and artificial intelligence (AI) models are transforming the landscape of GDM risk prediction and diagnosis. Traditional risk assessment tools rely on linear models and clinical risk factors, but ML algorithms can process high-dimensional. In particular, studies in high-risk populations such as South Asian women have demonstrated the utility of tailored ML models that account for ethnicity-specific risk profiles and behavioral predictors. For example, Periyathambi *et al*[115] applied ML techniques to predict postpartum diabetes risk in South Asian women with prior GDM, highlighting the importance of population-specific model development.

Despite these advancements, several challenges remain in translating biomarker discoveries and AI-driven risk assessment tools into clinical practice. Issues such as data standardization, external validation, regulatory approvals, and healthcare integration need to be addressed to ensure that these methods are cost-effective, accessible, and widely applicable across diverse populations. Future research should focus on multi-cohort validation studies, AI integration with wearable health technologies, and personalized follow-up protocols to enhance GDM screening and management strategies. Furthermore, the implementation of multi-omic strategies-encompassing genomic, transcriptomic, and metabolomic layers-is limited by high financial cost, infrastructure requirements, and lack of regulatory harmonization, particularly in low- and middle-income settings[116].

While several recent reviews have examined aspects of GDM prediction and screening, they have either narrowly focused on traditional risk models or discussed methodological limitations of emerging tools. For example, Germaine *et al* [117] emphasized challenges in implementing ML models-such as lack of data transparency and external validation-but did not address biomarker-based prediction strategies or their integration with ML frameworks. Similarly, ADA reviewed screening thresholds and clinical criteria but included only limited discussion of conventional biomarkers like CRP and HbA1c, without exploring recent advancements in placental, metabolic, genetic, or microRNA-based diagnostics [5]. In contrast, our review provides a comprehensive synthesis of validated and emerging biomarkers, while also evaluating state-of-the-art ML applications, thus offering a translational perspective that bridges biological discovery and computational modeling for early, individualized GDM risk stratification. To advance beyond existing reviews, we propose a stepwise integration framework in which biomarker panels-validated across multiple populations-serve as

primary triage tools, followed by ethnicity-specific ML risk models that dynamically update risk scores using longitudinal clinical and wearable-derived data. This combined approach could operationalize precision screening in routine antenatal care.

FOOTNOTES

Author contributions: Kaymak D and Erdinc-Ozgu AS jointly contributed to the writing, editing, and final approval of the manuscript.

Conflict-of-interest statement: The authors declare no conflict of interests for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country of origin: Türkiye

ORCID number: Didem Kaymak 0000-0002-2755-1932; Ayse Seval Ozgu-Erdinc 0000-0002-6132-5779.

S-Editor: Li L
L-Editor: A
P-Editor: Xu ZH

REFERENCES

1 **Cho NH**, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract* 2018; **138**: 271-281 [*RCA*] [PMID: 29496507 DOI: 10.1016/j.diabres.2018.02.023] [FullText]
2 **Weir GC**, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A. Beta-cell adaptation and decompensation during the progression of diabetes. *Diabetes* 2001; **50** Suppl 1: S154-S159 [*RCA*] [PMID: 11272180 DOI: 10.2337/diabetes.50.2007.s154] [FullText]
3 **Eades CE**, Burrows KA, Andreeva R, Stansfield DR, Evans JM. Prevalence of gestational diabetes in the United States and Canada: a systematic review and meta-analysis. *BMC Pregnancy Childbirth* 2024; **24**: 204 [*RCA*] [PMID: 38491497 DOI: 10.1186/s12884-024-06378-2] [FullText]
4 **Deputy NP**, Kim SY, Conrey EJ, Bullard KM. Prevalence and Changes in Preexisting Diabetes and Gestational Diabetes Among Women Who Had a Live Birth - United States, 2012-2016. *MMWR Morb Mortal Wkly Rep* 2018; **67**: 1201-1207 [*RCA*] [PMID: 30383743 DOI: 10.15585/mmwr.mm6743a2] [FullText] [Full Text(PDF)]
5 **American Diabetes Association Professional Practice Committee**. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025. *Diabetes Care* 2025; **48**: S27-S49 [*RCA*] [PMID: 39651986 DOI: 10.2337/dc25-S002] [FullText]
6 **Muhuza MPU**, Zhang L, Wu Q, Qi L, Chen D, Liang Z. The association between maternal HbA1c and adverse outcomes in gestational diabetes. *Front Endocrinol (Lausanne)* 2023; **14**: 1105899 [*RCA*] [PMID: 37008898 DOI: 10.3389/fendo.2023.1105899] [FullText]
7 **Kramer CK**, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. *Diabetologia* 2019; **62**: 905-914 [*RCA*] [PMID: 30843102 DOI: 10.1007/s00125-019-4840-2] [FullText]
8 ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. *Obstet Gynecol* 2018; **131**: e49-e64 [*RCA*] [PMID: 29370047 DOI: 10.1097/AOG.0000000000002501] [FullText]
9 **Rodrigo N**, Glastras SJ. The Emerging Role of Biomarkers in the Diagnosis of Gestational Diabetes Mellitus. *J Clin Med* 2018; **7**: 120 [*RCA*] [PMID: 29882903 DOI: 10.3390/jcm7060120] [FullText] [Full Text(PDF)]
10 **Zhao B**, Han X, Meng Q, Luo Q. Early second trimester maternal serum markers in the prediction of gestational diabetes mellitus. *J Diabetes Investig* 2018; **9**: 967-974 [*RCA*] [PMID: 29288571 DOI: 10.1111/jdi.12798] [FullText] [Full Text(PDF)]
11 **Poltavskiy E**, Kim DJ, Bang H. Comparison of screening scores for diabetes and prediabetes. *Diabetes Res Clin Pract* 2016; **118**: 146-153 [*RCA*] [PMID: 27371780 DOI: 10.1016/j.diabres.2016.06.022] [FullText]
12 **Mission JF**, Catov J, Deihl TE, Feghali M, Scifres C. Early Pregnancy Diabetes Screening and Diagnosis: Prevalence, Rates of Abnormal Test Results, and Associated Factors. *Obstet Gynecol* 2017; **130**: 1136-1142 [*RCA*] [PMID: 29016493 DOI: 10.1097/AOG.0000000000002277] [FullText]
13 **Sun H**, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract* 2022; **183**: 109119 [*RCA*] [PMID: 34879977 DOI: 10.1016/j.diabres.2021.109119] [FullText]
14 **Robbins C**, Boulet SL, Morgan I, D'Angelo DV, Zapata LB, Morrow B, Sharma A, Kroelinger CD. Disparities in Preconception Health Indicators - Behavioral Risk Factor Surveillance System, 2013-2015, and Pregnancy Risk Assessment Monitoring System, 2013-2014. *MMWR Surveill Summ* 2018; **67**: 1-16 [*RCA*] [PMID: 29346340 DOI: 10.15585/mmwr.ss6701a1] [FullText] [Full Text(PDF)]
15 **Yuen L**, Wong VW, Simmons D. Ethnic Disparities in Gestational Diabetes. *Curr Diab Rep* 2018; **18**: 68 [*RCA*] [PMID: 30039471 DOI: 10.1007/s11892-018-1040-2] [FullText]
16 **Zhu WW**, Yang HX, Wei YM, Yan J, Wang ZL, Li XL, Wu HR, Li N, Zhang MH, Liu XH, Zhang H, Wang YH, Niu JM, Gan YJ, Zhong LR, Wang YF, Kapur A. Evaluation of the value of fasting plasma glucose in the first prenatal visit to diagnose gestational diabetes mellitus in china. *Diabetes Care* 2013; **36**: 586-590 [*RCA*] [PMID: 23193214 DOI: 10.2337/dc12-1157] [FullText] [Full Text(PDF)]

17 **Mañé L**, Flores-Le Roux JA, Gómez N, Chillarón JJ, Llauradó G, Gortazar L, Payà A, Pedro-Botet J, Benaiges D. Association of first-trimester HbA1c levels with adverse pregnancy outcomes in different ethnic groups. *Diabetes Res Clin Pract* 2019; **150**: 202-210 [*RCA*] [PMID: 30880095 DOI: 10.1016/j.diabres.2019.03.017] [FullText]

18 **Boe B**, Barbour LA, Allshouse AA, Heyborne KD. Universal early pregnancy glycosylated hemoglobin A1c as an adjunct to Carpenter-Coustan screening: an observational cohort study. *Am J Obstet Gynecol MFM* 2019; **1**: 24-32 [*RCA*] [PMID: 33319754 DOI: 10.1016/j.ajogmf.2019.02.003] [FullText]

19 **Chen L**, Pocobelli G, Yu O, Shortreed SM, Osmundson SS, Fuller S, Wartko PD, Mcculloch D, Warwick S, Newton KM, Dublin S. Early Pregnancy Hemoglobin A1C and Pregnancy Outcomes: A Population-Based Study. *Am J Perinatol* 2019; **36**: 1045-1053 [*RCA*] [PMID: 30500961 DOI: 10.1055/s-0038-1675619] [FullText]

20 **Osmundson SS**, Zhao BS, Kunz L, Wang E, Popat R, Nimbal VC, Palaniappan LP. First Trimester Hemoglobin A1c Prediction of Gestational Diabetes. *Am J Perinatol* 2016; **33**: 977-982 [*RCA*] [PMID: 27120479 DOI: 10.1055/s-0036-1581055] [FullText]

21 **Metzger BE**, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. *N Engl J Med* 2008; **358**: 1991-2002 [*RCA*] [PMID: 18463375 DOI: 10.1056/NEJMoa0707943] [FullText]

22 **Metzger BE**, Gabbe SG, Persson B, Buchanan TA, Catalano PM, Damm P, Dyer AR, Hod M, Kitzmiller JL, Lowe LP, McIntyre HD, Oats JJ, Omori Y; International Association of Diabetes & Pregnancy Study Groups (IADPSG) Consensus Panel Writing Group and the Hyperglycemia & Adverse Pregnancy Outcome (HAPO) Study Steering Committee. The diagnosis of gestational diabetes mellitus: new paradigms or status quo? *J Matern Fetal Neonatal Med* 2012; **25**: 2564-2569 [*RCA*] [PMID: 22876884 DOI: 10.3109/14767058.2012.718002] [FullText]

23 Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization Guideline. *Diabetes Res Clin Pract* 2014; **103**: 341-363 [*RCA*] [PMID: 24847517 DOI: 10.1016/j.diabres.2013.10.012] [FullText]

24 **Walker JD**. NICE guidance on diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. NICE clinical guideline 63. London, March 2008. *Diabet Med* 2008; **25**: 1025-1027 [*RCA*] [PMID: 19183306 DOI: 10.1111/j.1464-5491.2008.02532.x] [FullText]

25 **Defronzo RA**. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes* 2009; **58**: 773-795 [*RCA*] [PMID: 19336687 DOI: 10.2337/db09-9028] [FullText] [Full Text(PDF)]

26 **Zraika S**, Hull RL, Verchere CB, Clark A, Potter KJ, Fraser PE, Raleigh DP, Kahn SE. Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? *Diabetologia* 2010; **53**: 1046-1056 [*RCA*] [PMID: 20182863 DOI: 10.1007/s00125-010-1671-6] [FullText] [Full Text(PDF)]

27 **Ashcroft FM**, Rohm M, Clark A, Brereton MF. Is Type 2 Diabetes a Glycogen Storage Disease of Pancreatic β Cells? *Cell Metab* 2017; **26**: 17-23 [*RCA*] [PMID: 28683284 DOI: 10.1016/j.cmet.2017.05.014] [FullText]

28 **Butler AE**, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. *Diabetes* 2003; **52**: 102-110 [*RCA*] [PMID: 12502499 DOI: 10.2337/diabetes.52.1.102] [FullText]

29 **Rahier J**, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. *Diabetes Obes Metab* 2008; **10** Suppl 4: 32-42 [*RCA*] [PMID: 18834431 DOI: 10.1111/j.1463-1326.2008.00969.x] [FullText]

30 **Van Assche FA**, Aerts L, De Prins F. A morphological study of the endocrine pancreas in human pregnancy. *Br J Obstet Gynaecol* 1978; **85**: 818-820 [*RCA*] [PMID: 363135 DOI: 10.1111/j.1471-0528.1978.tb15835.x] [FullText]

31 **Catalano PM**. Trying to understand gestational diabetes. *Diabet Med* 2014; **31**: 273-281 [*RCA*] [PMID: 24341419 DOI: 10.1111/dme.12381] [FullText]

32 **Barbour LA**, McCurdy CE, Hernandez TL, Kirwan JP, Catalano PM, Friedman JE. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. *Diabetes Care* 2007; **30** Suppl 2: S112-S119 [*RCA*] [PMID: 17596458 DOI: 10.2337/dc07-s202] [Full Text]

33 **Friedman JE**, Kirwan JP, Jing M, Presley L, Catalano PM. Increased skeletal muscle tumor necrosis factor-alpha and impaired insulin signaling persist in obese women with gestational diabetes mellitus 1 year postpartum. *Diabetes* 2008; **57**: 606-613 [*RCA*] [PMID: 18083784 DOI: 10.2337/db07-1356] [FullText]

34 **Pérez-Pérez A**, Maymó JL, Gambino YP, Guadix P, Dueñas JL, Varone CL, Sánchez-Margalet V. Activated translation signaling in placenta from pregnant women with gestational diabetes mellitus: possible role of leptin. *Horm Metab Res* 2013; **45**: 436-442 [*RCA*] [PMID: 23386416 DOI: 10.1055/s-0032-1333276] [FullText]

35 **Koch CE**, Lowe C, Pretz D, Steger J, Williams LM, Tups A. High-fat diet induces leptin resistance in leptin-deficient mice. *J Neuroendocrinol* 2014; **26**: 58-67 [*RCA*] [PMID: 24382295 DOI: 10.1111/jne.12131] [FullText]

36 **Williams MA**, Qiu C, Muy-Rivera M, Vadachkoria S, Song T, Luthy DA. Plasma adiponectin concentrations in early pregnancy and subsequent risk of gestational diabetes mellitus. *J Clin Endocrinol Metab* 2004; **89**: 2306-2311 [*RCA*] [PMID: 15126557 DOI: 10.1210/jc.2003-031201] [FullText]

37 **Fasshauer M**, Blüher M, Stumvoll M. Adipokines in gestational diabetes. *Lancet Diabetes Endocrinol* 2014; **2**: 488-499 [*RCA*] [PMID: 24731659 DOI: 10.1016/S2213-8587(13)70176-1] [FullText]

38 **Retnakaran R**, Hanley AJ, Raif N, Connelly PW, Sermer M, Zinman B. Reduced adiponectin concentration in women with gestational diabetes: a potential factor in progression to type 2 diabetes. *Diabetes Care* 2004; **27**: 799-800 [*RCA*] [PMID: 14988306 DOI: 10.2337/diacare.27.3.799] [FullText]

39 **Rojas-Rodriguez R**, Lifshitz LM, Bellve KD, Min SY, Pires J, Leung K, Boeras C, Sert A, Draper JT, Corvera S, Moore Simas TA. Human adipose tissue expansion in pregnancy is impaired in gestational diabetes mellitus. *Diabetologia* 2015; **58**: 2106-2114 [*RCA*] [PMID: 26067361 DOI: 10.1007/s00125-015-3662-0] [FullText] [Full Text(PDF)]

40 **Lappas M**. Effect of pre-existing maternal obesity, gestational diabetes and adipokines on the expression of genes involved in lipid metabolism in adipose tissue. *Metabolism* 2014; **63**: 250-262 [*RCA*] [PMID: 24262292 DOI: 10.1016/j.metabol.2013.10.001] [FullText]

41 **Augustin R**. The protein family of glucose transport facilitators: It's not only about glucose after all. *IUBMB Life* 2010; **62**: 315-333 [*RCA*] [PMID: 20209635 DOI: 10.1002/iub.315] [FullText]

42 **Hiden U**, Maier A, Bilban M, Ghaffari-Tabrizi N, Wadsack C, Lang I, Dohr G, Desoye G. Insulin control of placental gene expression shifts from mother to foetus over the course of pregnancy. *Diabetologia* 2006; **49**: 123-131 [*RCA*] [PMID: 16344925 DOI: 10.1007/s00125-005-0054-x] [FullText]

43 **Jansson T**, Powell TL. Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches. *Clin Sci (Lond)* 2007; **113**: 1-13 [*RCA*] [PMID: 17536998 DOI: 10.1042/CS20060339] [FullText]

44 **Catalano PM**, McIntyre HD, Cruickshank JK, McCance DR, Dyer AR, Metzger BE, Lowe LP, Trimble ER, Coustan DR, Hadden DR, Persson B, Hod M, Oats JJ; HAPO Study Cooperative Research Group. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. *Diabetes Care* 2012; **35**: 780-786 [*RCA*] [PMID: 22357187 DOI: 10.2337/dc11-1790] [Full Text] [Full Text(PDF)]

45 **Lesseur C**, Chen J. Adverse Maternal Metabolic Intrauterine Environment and Placental Epigenetics: Implications for Fetal Metabolic Programming. *Curr Environ Health Rep* 2018; **5**: 531-543 [*RCA*] [PMID: 30267228 DOI: 10.1007/s40572-018-0217-9] [FullText]

46 **Biomarkers Definitions Working Group**. . Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin Pharmacol Ther* 2001; **69**: 89-95 [*RCA*] [PMID: 11240971 DOI: 10.1067/mcp.2001.113989] [FullText]

47 **Liu Y**, Li DY, Bolatai A, Wu N. Progress in Research on Biomarkers of Gestational Diabetes Mellitus and Preeclampsia. *Diabetes Metab Syndr Obes* 2023; **16**: 3807-3815 [*RCA*] [PMID: 38028997 DOI: 10.2147/DMSO.S433179] [FullText] [Full Text(PDF)]

48 **Duo Y**, Song S, Zhang Y, Qiao X, Xu J, Zhang J, Peng Z, Chen Y, Nie X, Sun Q, Yang X, Wang A, Sun W, Fu Y, Dong Y, Lu Z, Yuan T, Zhao W. Predictability of HOMA-IR for Gestational Diabetes Mellitus in Early Pregnancy Based on Different First Trimester BMI Values. *J Pers Med* 2022; **13**: 60 [*RCA*] [PMID: 36675721 DOI: 10.3390/jpm13010060] [FullText]

49 **Grewal E**, Kansara S, Kachhawa G, Ammini AC, Kriplani A, Aggarwal N, Gupta N, Khadgawat R. Prediction of gestational diabetes mellitus at 24 to 28 weeks of gestation by using first-trimester insulin sensitivity indices in Asian Indian subjects. *Metabolism* 2012; **61**: 715-720 [*RCA*] [PMID: 22146095 DOI: 10.1016/j.metabol.2011.10.009] [FullText]

50 **Li MY**, Rawal S, Hinkle SN, Zhu YY, Tekola-Ayele F, Tsai MY, Liu SM, Zhang CL. Sex Hormone-binding Globulin, Cardiometabolic Biomarkers, and Gestational Diabetes: A Longitudinal Study and Meta-analysis. *Matern Fetal Med* 2020; **2**: 2-9 [*RCA*] [PMID: 32776014 DOI: 10.1097/FM9.0000000000000037] [FullText] [Full Text(PDF)]

51 **Corcoran SM**, Achamallah N, Loughlin JO, Stafford P, Dicker P, Malone FD, Breathnach F. First trimester serum biomarkers to predict gestational diabetes in a high-risk cohort: Striving for clinically useful thresholds. *Eur J Obstet Gynecol Reprod Biol* 2018; **222**: 7-12 [*RCA*] [PMID: 29328940 DOI: 10.1016/j.ejogrb.2017.12.051] [FullText]

52 **Seyhanli Z**, Bayraktar B, Bucak M, Karabay G, Tokgoz Cakir B, Ulusoy CO, Aktemur G, Sefik SO, Topkara Sucu S, Celen S, Caglar AT. The Association Between Resolvin D1 Levels and Gestational Diabetes Mellitus: Implications for Perinatal Outcomes. *Gynecol Obstet Reprod Med* 2024; **30**: 75-82 [DOI: 10.21613/gorm.2023.1505] [FullText]

53 **Herrera E**. Lipid metabolism in pregnancy and its consequences in the fetus and newborn. *Endocrine* 2002; **19**: 43-55 [*RCA*] [PMID: 12583601 DOI: 10.1385/ENDO:19:1:43] [FullText]

54 **Song L**, Wang N, Peng Y, Sun B, Cui W. Placental lipid transport and content in response to maternal overweight and gestational diabetes mellitus in human term placenta. *Nutr Metab Cardiovasc Dis* 2022; **32**: 692-702 [*RCA*] [PMID: 35109996 DOI: 10.1016/j.numecd.2021.12.018] [FullText]

55 **Herrera E**, Ortega-Senovilla H. Disturbances in lipid metabolism in diabetic pregnancy - Are these the cause of the problem? *Best Pract Res Clin Endocrinol Metab* 2010; **24**: 515-525 [*RCA*] [PMID: 20832733 DOI: 10.1016/j.beem.2010.05.006] [FullText]

56 **Ryckman KK**, Spracklen CN, Smith CJ, Robinson JG, Saftlas AF. Maternal lipid levels during pregnancy and gestational diabetes: a systematic review and meta-analysis. *BJOG* 2015; **122**: 643-651 [*RCA*] [PMID: 25612005 DOI: 10.1111/1471-0528.13261] [FullText]

57 **Cuffe JS**, Xu ZC, Perkins AV. Biomarkers of oxidative stress in pregnancy complications. *Biomark Med* 2017; **11**: 295-306 [*RCA*] [PMID: 28157383 DOI: 10.2217/bmm-2016-0250] [FullText]

58 **Barrios V**, Chowen JA, Martín-Rivada Á, Guerra-Cantera S, Pozo J, Yakar S, Rosenfeld RG, Pérez-Jurado LA, Suárez J, Argente J. Pregnancy-Associated Plasma Protein (PAPP)-A2 in Physiology and Disease. *Cells* 2021; **10**: 3576 [*RCA*] [PMID: 34944082 DOI: 10.3390/cells10123576] [FullText] [Full Text(PDF)]

59 **Al-Shafei AI**, Rayis DA, Mohieldein AH, El-Gendy OA, Adam I. Maternal early pregnancy serum level of 25-Hydroxyvitamin D and risk of gestational diabetes mellitus. *Int J Gynaecol Obstet* 2021; **152**: 382-385 [*RCA*] [PMID: 32976628 DOI: 10.1002/ijgo.13389] [FullText]

60 **Tanase DM**, Gosav EM, Botoc T, Floria M, Tarniceriu CC, Maranduca MA, Haisan A, Cucu AI, Rezus C, Costea CF. Depiction of Branched-Chain Amino Acids (BCAAs) in Diabetes with a Focus on Diabetic Microvascular Complications. *J Clin Med* 2023; **12**: 6053 [*RCA*] [PMID: 37762992 DOI: 10.3390/jcm12186053] [FullText]

61 **Perichart-Perera O**, Muñoz-Manrique C, Reyes-López A, Tolentino-Dolores M, Espino Y Sosa S, Ramírez-González MC. Metabolic markers during pregnancy and their association with maternal and newborn weight status. *PLoS One* 2017; **12**: e0180874 [*RCA*] [PMID: 28749954 DOI: 10.1371/journal.pone.0180874] [FullText] [Full Text(PDF)]

62 **Gebes O**, Kale İ, Beser Gebes T, Muhcu M. Investigation of Serum Cartonectin Concentrations in Pregnant Women with Gestational Diabetes Mellitus; a Prospective Non-Interventional Cohort Study. *Gynecol Obstet Reprod Med* 2024; **30**: 33-38 [DOI: 10.21613/gorm.2023.1471] [Full Text]

63 **Syngelaki A**, Visser GH, Krithinakis K, Wright A, Nicolaides KH. First trimester screening for gestational diabetes mellitus by maternal factors and markers of inflammation. *Metabolism* 2016; **65**: 131-137 [*RCA*] [PMID: 26892524 DOI: 10.1016/j.metabol.2015.10.029] [Full Text]

64 **Wolf M**, Sandler L, Hsu K, Vossen-Smirnakis K, Ecker JL, Thadhani R. First-trimester C-reactive protein and subsequent gestational diabetes. *Diabetes Care* 2003; **26**: 819-824 [*RCA*] [PMID: 12610043 DOI: 10.2337/diacare.26.3.819] [FullText]

65 **Ozgu-Erdinc AS**, Yilmaz S, Yeral MI, Seckin KD, Erkaya S, Danisman AN. Prediction of gestational diabetes mellitus in the first trimester: comparison of C-reactive protein, fasting plasma glucose, insulin and insulin sensitivity indices. *J Matern Fetal Neonatal Med* 2015; **28**: 1957-1962 [*RCA*] [PMID: 25283990 DOI: 10.3109/14767058.2014.973397] [FullText]

66 **Fève B**, Bastard JP. The role of interleukins in insulin resistance and type 2 diabetes mellitus. *Nat Rev Endocrinol* 2009; **5**: 305-311 [*RCA*] [PMID: 19399017 DOI: 10.1038/nrendo.2009.62] [FullText]

67 **Qiu J**, Song R, Chen L, Yang D, Cheng W, Zhu W. The association between inflammatory indices in early pregnancy and the risk of gestational diabetes mellitus in Chinese population. *BMC Pregnancy Childbirth* 2025; **25**: 151 [*RCA*] [PMID: 39939977 DOI: 10.1186/s12884-025-07238-3] [FullText] [Full Text(PDF)]

68 **Schuitemaker JHN**, Beernink RHJ, Franx A, Cremers TIFH, Koster MPH. First trimester secreted Frizzled-Related Protein 4 and other adipokine serum concentrations in women developing gestational diabetes mellitus. *PLoS One* 2020; **15**: e0242423 [*RCA*] [PMID: 33206702 DOI: 10.1371/journal.pone.0242423] [FullText] [Full Text(PDF)]

69 **Kansu-Celik H**, Ozgu-Erdinc AS, Kisa B, Findik RB, Yilmaz C, Tasci Y. Prediction of gestational diabetes mellitus in the first trimester: comparison of maternal fetuin-A, N-terminal proatrial natriuretic peptide, high-sensitivity C-reactive protein, and fasting glucose levels. *Arch Endocrinol Metab* 2019; **63**: 121-127 [*RCA*] [PMID: 31038593 DOI: 10.20945/2359-3997000000126] [FullText] [Full Text(PDF)]

70 **Florian AR**, Cruciat G, Pop RM, Staicu A, Daniel M, Florin S. Predictive role of altered leptin, adiponectin and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid secretion in gestational diabetes mellitus. *Exp Ther Med* 2021; **21**: 520 [*RCA*] [PMID: 33815593 DOI: 10.3892/etm.2021.9951] [FullText] [Full Text(PDF)]

71 **Bozkurt L**, Göbl CS, Baumgartner-Parzer S, Luger A, Pacini G, Kautzky-Willer A. Adiponectin and Leptin at Early Pregnancy: Association to Actual Glucose Disposal and Risk for GDM-A Prospective Cohort Study. *Int J Endocrinol* 2018; **2018**: 5463762 [*RCA*] [PMID: 30123262 DOI: 10.1155/2018/5463762] [FullText] [Full Text(PDF)]

72 **Castillo-Castrejon M**, Powell TL. Placental Nutrient Transport in Gestational Diabetic Pregnancies. *Front Endocrinol (Lausanne)* 2017; **8**: 306 [*RCA*] [PMID: 29163373 DOI: 10.3389/fendo.2017.00306] [FullText] [Full Text(PDF)]

73 **Bibee KP**, Illsley NP, Moley KH. Asymmetric syncytial expression of GLUT9 splice variants in human term placenta and alterations in diabetic pregnancies. *Reprod Sci* 2011; **18**: 20-27 [*RCA*] [PMID: 20926839 DOI: 10.1177/1933719110380276] [FullText] [Full Text(PDF)]

74 **Illsley NP**, Sellers MC, Wright RL. Glycaemic regulation of glucose transporter expression and activity in the human placenta. *Placenta* 1998; **19**: 517-524 [*RCA*] [PMID: 9778125 DOI: 10.1016/s0143-4004(98)91045-1] [FullText]

75 **Visiedo F**, Bugatto F, Quintero-Prado R, Cózar-Castellano I, Bartha JL, Perdomo G. Glucose and Fatty Acid Metabolism in Placental Explants From Pregnancies Complicated With Gestational Diabetes Mellitus. *Reprod Sci* 2015; **22**: 798-801 [*RCA*] [PMID: 25491487 DOI: 10.1177/1933719114561558] [FullText]

76 **Johns EC**, Denison FC, Norman JE, Reynolds RM. Gestational Diabetes Mellitus: Mechanisms, Treatment, and Complications. *Trends Endocrinol Metab* 2018; **29**: 743-754 [*RCA*] [PMID: 30297319 DOI: 10.1016/j.tem.2018.09.004] [FullText]

77 **Dey M**, Singh S, Tiwari R, Nair VG, Arora D, Tiwari S. Pregnancy Outcome in First 50 Sars-Cov-2 Positive Patients At Our Center. *Gynecol Obstet Reprod Med* 2021; **27**: 11-16 [*RCA*] [DOI: 10.21613/gorm.2021.1176] [FullText]

78 **Dereke J**, Nilsson C, Strevens H, Landin-Olsson M, Hillman M. Pregnancy-associated plasma protein-A2 levels are increased in early-pregnancy gestational diabetes: a novel biomarker for early risk estimation. *Diabet Med* 2020; **37**: 131-137 [*RCA*] [PMID: 31340069 DOI: 10.1111/dme.14088] [FullText]

79 **Inan C**, Varol FG, Erzincan SG, Uzun I, Sutcu H, Sayin NC. Use of prokineticin-1 (PROK1), pregnancy-associated plasma protein A (PAPP-A) and PROK1/PAPP-A ratio to predict adverse pregnancy outcomes in the first trimester: a prospective study. *J Matern Fetal Neonatal Med* 2018; **31**: 2685-2692 [*RCA*] [PMID: 28675948 DOI: 10.1080/14767058.2017.1351536] [FullText]

80 **Mosimann B**, Amylidi S, Risch L, Wiedemann U, Surbek D, Baumann M, Stettler C, Raio L. First-Trimester Placental Growth Factor in Screening for Gestational Diabetes. *Fetal Diagn Ther* 2016; **39**: 287-291 [*RCA*] [PMID: 26421599 DOI: 10.1159/000441027] [FullText]

81 **Yuan Y**, He W, Fan X, Liang J, Cao Z, Li L. Serum afamin levels in predicting gestational diabetes mellitus and preeclampsia: A systematic review and meta-analysis. *Front Endocrinol (Lausanne)* 2023; **14**: 1157114 [*RCA*] [PMID: 37033215 DOI: 10.3389/fendo.2023.1157114] [Full Text]

82 **Alanen J**, Appelblom H, Korpimaki T, Kouru H, Sairanen M, Gissler M, Ryynanen M, Nevalainen J. Glycosylated fibronectin as a first trimester marker for gestational diabetes. *Arch Gynecol Obstet* 2020; **302**: 853-860 [*RCA*] [PMID: 32653948 DOI: 10.1007/s00404-020-05670-8] [FullText] [Full Text(PDF)]

83 **Heusler I**, Biron-Shental T, Farladansky-Gershnabel S, Pasternak Y, Kidron D, Vulih-Shuitsman I, Einbinder Y, Cohen-Hagai K, Benchetrit S, Zitman-Gal T. Enhanced expression of Galectin-3 in gestational diabetes. *Nutr Metab Cardiovasc Dis* 2021; **31**: 1791-1797 [*RCA*] [PMID: 34023181 DOI: 10.1016/j.numecd.2021.03.002] [FullText]

84 **Zhang Y**, Zhang HH, Lu JH, Zheng SY, Long T, Li YT, Wu WZ, Wang F. Changes in serum adipocyte fatty acid-binding protein in women with gestational diabetes mellitus and normal pregnant women during mid- and late pregnancy. *J Diabetes Investig* 2016; **7**: 797-804 [*RCA*] [PMID: 27181269 DOI: 10.1111/jdi.12484] [FullText] [Full Text(PDF)]

85 **Piani F**, Tossetta G, Fantone S, Agostinis C, Di Simone N, Mandalà M, Bulla R, Marzioni D, Borghi C. First Trimester CD93 as a Novel Marker of Preeclampsia and Its Complications: A Pilot Study. *High Blood Press Cardiovasc Prev* 2023; **30**: 591-594 [*RCA*] [PMID: 38010536 DOI: 10.1007/s40292-023-00608-y] [FullText]

86 **Tossetta G**, Fantone S, Gesuita R, Di Renzo GC, Meyyazhagan A, Tersigni C, Scambia G, Di Simone N, Marzioni D. HtrA1 in Gestational Diabetes Mellitus: A Possible Biomarker? *Diagnostics (Basel)* 2022; **12**: 2705 [*RCA*] [PMID: 36359548 DOI: 10.3390/diagnostics12112705] [FullText]

87 **Kwak SH**, Kim SH, Cho YM, Go MJ, Cho YS, Choi SH, Moon MK, Jung HS, Shin HD, Kang HM, Cho NH, Lee IK, Kim SY, Han BG, Jang HC, Park KS. A genome-wide association study of gestational diabetes mellitus in Korean women. *Diabetes* 2012; **61**: 531-541 [*RCA*] [PMID: 22233651 DOI: 10.2337/db11-1034] [FullText] [Full Text(PDF)]

88 **Grant SFA**. The TCF7L2 Locus: A Genetic Window Into the Pathogenesis of Type 1 and Type 2 Diabetes. *Diabetes Care* 2019; **42**: 1624-1629 [*RCA*] [PMID: 31409726 DOI: 10.2337/dci19-0001] [FullText] [Full Text(PDF)]

89 **Huopio H**, Cederberg H, Vangipurapu J, Hakkarainen H, Pääkkönen M, Kuulasmaa T, Heinonen S, Laakso M. Association of risk variants for type 2 diabetes and hyperglycemia with gestational diabetes. *Eur J Endocrinol* 2013; **169**: 291-297 [*RCA*] [PMID: 23761423 DOI: 10.1530/EJE-13-0286] [FullText]

90 **Langenberg C**, Pascoe L, Mari A, Tura A, Laakso M, Frayling TM, Barroso I, Loos RJ, Wareham NJ, Walker M; RISC Consortium. Common genetic variation in the melatonin receptor 1B gene (MTNR1B) is associated with decreased early-phase insulin response. *Diabetologia* 2009; **52**: 1537-1542 [*RCA*] [PMID: 19455304 DOI: 10.1007/s00125-009-1392-x] [FullText] [Full Text(PDF)]

91 **Song JY**, Wang HJ, Ma J, Xu ZY, Hinney A, Hebebrand J, Wang Y. Association of the rs10830963 polymorphism in MTNR1B with fasting glucose levels in Chinese children and adolescents. *Obes Facts* 2011; **4**: 197-203 [*RCA*] [PMID: 21701235 DOI: 10.1159/000329306] [Full Text]

92 **Matharoo K**, Arora P, Bhanwer AJ. Association of adiponectin (AdipoQ) and sulphonylurea receptor (ABCC8) gene polymorphisms with Type 2 Diabetes in North Indian population of Punjab. *Gene* 2013; **527**: 228-234 [*RCA*] [PMID: 23764562 DOI: 10.1016/j.gene.2013.05.075] [FullText]

93 **Yoffe L**, Polsky A, Gilam A, Raff C, Mecacci F, Ognibene A, Crispi F, Gratacós E, Kanety H, Mazaki-Tovi S, Shomron N, Hod M. Early diagnosis of gestational diabetes mellitus using circulating microRNAs. *Eur J Endocrinol* 2019; **181**: 565-577 [*RCA*] [PMID: 31539877 DOI: 10.1530/EJE-19-0206] [FullText]

94 **Zhao C**, Dong J, Jiang T, Shi Z, Yu B, Zhu Y, Chen D, Xu J, Huo R, Dai J, Xia Y, Pan S, Hu Z, Sha J. Early second-trimester serum miRNA

profiling predicts gestational diabetes mellitus. *PLoS One* 2011; **6**: e23925 [*RCA*] [PMID: 21887347 DOI: 10.1371/journal.pone.0023925] [FullText] [Full Text(PDF)]

95 **Wang P**, Wang Z, Liu G, Jin C, Zhang Q, Man S, Wang Z. miR-657 Promotes Macrophage Polarization toward M1 by Targeting FAM46C in Gestational Diabetes Mellitus. *Mediators Inflamm* 2019; **2019**: 4851214 [*RCA*] [PMID: 31915414 DOI: 10.1155/2019/4851214] [FullText] [Full Text(PDF)]

96 **Herrera-Van Oostdam AS**, Toro-Ortíz JC, López JA, Noyola DE, García-López DA, Durán-Figueroa NV, Martínez-Martínez E, Portales-Pérez DP, Salgado-Bustamante M, López-Hernández Y. Placental exosomes isolated from urine of patients with gestational diabetes exhibit a differential profile expression of microRNAs across gestation. *Int J Mol Med* 2020; **46**: 546-560 [*RCA*] [PMID: 32626972 DOI: 10.3892/ijmm.2020.4626] [FullText] [Full Text(PDF)]

97 **Lamadrid-Romero M**, Solís KH, Cruz-Reséndiz MS, Pérez JE, Díaz NF, Flores-Herrera H, García-López G, Perichart O, Reyes-Muñoz E, Arenas-Huertero F, Eguía-Aguilar P, Molina-Hernández A. Central nervous system development-related microRNAs levels increase in the serum of gestational diabetic women during the first trimester of pregnancy. *Neurosci Res* 2018; **130**: 8-22 [*RCA*] [PMID: 28803788 DOI: 10.1016/j.neures.2017.08.003] [FullText]

98 **Juchnicka I**, Kuźmicki M, Niemira M, Bielska A, Sidorkiewicz I, Zbucka-Krętowska M, Krętowski AJ, Szamatowicz J. miRNAs as Predictive Factors in Early Diagnosis of Gestational Diabetes Mellitus. *Front Endocrinol (Lausanne)* 2022; **13**: 839344 [*RCA*] [PMID: 35340328 DOI: 10.3389/fendo.2022.839344] [FullText] [Full Text(PDF)]

99 **Ye Z**, Wang S, Huang X, Chen P, Deng L, Li S, Lin S, Wang Z, Liu B. Plasma Exosomal miRNAs Associated With Metabolism as Early Predictor of Gestational Diabetes Mellitus. *Diabetes* 2022; **71**: 2272-2283 [*RCA*] [PMID: 35926094 DOI: 10.2337/db21-0909] [FullText] [Full Text(PDF)]

100 **Yu J**, Ren J, Ren Y, Wu Y, Zeng Y, Zhang Q, Xiao X. Using metabolomics and proteomics to identify the potential urine biomarkers for prediction and diagnosis of gestational diabetes. *EBioMedicine* 2024; **101**: 105008 [*RCA*] [PMID: 38368766 DOI: 10.1016/j.ebiom.2024.105008] [FullText] [Full Text(PDF)]

101 **Wang X**, Zhang Y, Zheng W, Wang J, Wang Y, Song W, Liang S, Guo C, Ma X, Li G. Dynamic changes and early predictive value of branched-chain amino acids in gestational diabetes mellitus during pregnancy. *Front Endocrinol (Lausanne)* 2022; **13**: 1000296 [*RCA*] [PMID: 36313758 DOI: 10.3389/fendo.2022.1000296] [FullText] [Full Text(PDF)]

102 **Gao J**, Yang T, Song B, Ma X, Ma Y, Lin X, Wang H. Abnormal tryptophan catabolism in diabetes mellitus and its complications: Opportunities and challenges. *Biomed Pharmacother* 2023; **166**: 115395 [*RCA*] [PMID: 37657259 DOI: 10.1016/j.biopha.2023.115395] [Full Text]

103 **Law KP**, Han TL, Mao X, Zhang H. Tryptophan and purine metabolites are consistently upregulated in the urinary metabolome of patients diagnosed with gestational diabetes mellitus throughout pregnancy: A longitudinal metabolomics study of Chinese pregnant women part 2. *Clin Chim Acta* 2017; **468**: 126-139 [*RCA*] [PMID: 28238935 DOI: 10.1016/j.cca.2017.02.018] [FullText]

104 **Meikle PJ**, Summers SA. Sphingolipids and phospholipids in insulin resistance and related metabolic disorders. *Nat Rev Endocrinol* 2017; **13**: 79-91 [*RCA*] [PMID: 27767036 DOI: 10.1038/nrendo.2016.169] [FullText]

105 **Fu WJ**, Wang DJ, Deng RT, Huang ZH, Chen ML, Jang YM, Wen S, Yang HL, Huang XZ. Urinary liver-type fatty acid-binding protein change in gestational diabetes mellitus. *Diabetes Res Clin Pract* 2015; **109**: e36-e38 [*RCA*] [PMID: 26254248 DOI: 10.1016/j.diabres.2015.02.029] [FullText]

106 **Hu Z**, Hou J, Zhang M. Levels of inter-alpha-trypsin inhibitor heavy chain H4 urinary polypeptide in gestational diabetes mellitus. *Syst Biol Reprod Med* 2021; **67**: 428-437 [*RCA*] [PMID: 34607479 DOI: 10.1080/19396368.2021.1977869] [FullText]

107 **Zhang Z**, Yang L, Han W, Wu Y, Zhang L, Gao C, Jiang K, Liu Y, Wu H. Machine Learning Prediction Models for Gestational Diabetes Mellitus: Meta-analysis. *J Med Internet Res* 2022; **24**: e26634 [*RCA*] [PMID: 35294369 DOI: 10.2196/26634] [FullText]

108 **Zaky H**, Fthenou E, Srour L, Farrell T, Bashir M, El Hajj N, Alam T. Machine learning based model for the early detection of Gestational Diabetes Mellitus. *BMC Med Inform Decis Mak* 2025; **25**: 130 [*RCA*] [PMID: 40082942 DOI: 10.1186/s12911-025-02947-3] [FullText] [Full Text(PDF)]

109 **Kaya Y**, Bütün Z, Çelik Ö, Salik EA, Tahta T, Yavuz AA. The early prediction of gestational diabetes mellitus by machine learning models. *BMC Pregnancy Childbirth* 2024; **24**: 574 [*RCA*] [PMID: 39217284 DOI: 10.1186/s12884-024-06783-7] [FullText] [Full Text(PDF)]

110 **Liu H**, Li J, Leng J, Wang H, Liu J, Li W, Liu H, Wang S, Ma J, Chan JC, Yu Z, Hu G, Li C, Yang X. Machine learning risk score for prediction of gestational diabetes in early pregnancy in Tianjin, China. *Diabetes Metab Res Rev* 2021; **37**: e3397 [*RCA*] [PMID: 32845061 DOI: 10.1002/dmrr.3397] [FullText]

111 **Wu YT**, Zhang CJ, Mol BW, Kawai A, Li C, Chen L, Wang Y, Sheng JZ, Fan JX, Shi Y, Huang HF. Early Prediction of Gestational Diabetes Mellitus in the Chinese Population *via* Advanced Machine Learning. *J Clin Endocrinol Metab* 2021; **106**: e1191-e1205 [*RCA*] [PMID: 33351102 DOI: 10.1210/clinem/dgaa899] [FullText]

112 **Kang BS**, Lee SU, Hong S, Choi SK, Shin JE, Wie JH, Jo YS, Kim YH, Kil K, Chung YH, Jung K, Hong H, Park IY, Ko HS. Prediction of gestational diabetes mellitus in Asian women using machine learning algorithms. *Sci Rep* 2023; **13**: 13356 [*RCA*] [PMID: 37587201 DOI: 10.1038/s41598-023-39680-8] [FullText]

113 **Belsti Y**, Moran L, Du L, Mousa A, De Silva K, Enticott J, Teede H. Comparison of machine learning and conventional logistic regression-based prediction models for gestational diabetes in an ethnically diverse population; the Monash GDM Machine learning model. *Int J Med Inform* 2023; **179**: 105228 [*RCA*] [PMID: 37774429 DOI: 10.1016/j.ijmedinf.2023.105228] [FullText]

114 **Zhao M**, Yao Z, Zhang Y, Ma L, Pang W, Ma S, Xu Y, Wei L. Predictive value of machine learning for the progression of gestational diabetes mellitus to type 2 diabetes: a systematic review and meta-analysis. *BMC Med Inform Decis Mak* 2025; **25**: 18 [*RCA*] [PMID: 39806461 DOI: 10.1186/s12911-024-02848-x] [FullText] [Full Text(PDF)]

115 **Periyathambi N**, Parkhi D, Ghebremichael-Weldeselassie Y, Patel V, Sukumar N, Siddharthan R, Narlikar L, Saravanan P. Machine learning prediction of non-attendance to postpartum glucose screening and subsequent risk of type 2 diabetes following gestational diabetes. *PLoS One* 2022; **17**: e0264648 [*RCA*] [PMID: 35255105 DOI: 10.1371/journal.pone.0264648] [FullText] [Full Text(PDF)]

116 **Hassan A**, Ahmad SG, Iqbal T, Munir EU, Ayyub K, Ramzan N. Enhanced Model for Gestational Diabetes Mellitus Prediction Using a Fusion Technique of Multiple Algorithms with Explainability. *Int J Comput Intell Syst* 2025; **18**: 47 [DOI: 10.1007/s44196-025-00760-4] [FullText]

117 **Germaine M**, Healy G, Egan B. Lack of Data Sharing Despite Data Availability Statements in Studies Using Machine Learning Models for Prediction of Gestational Diabetes Mellitus. *Diabetes Care* 2024; **47**: e78-e79 [*RCA*] [PMID: 39159281 DOI: 10.2337/dc24-1483] [FullText]

Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: office@baishideng.com
Help Desk: https://www.f6publishing.com/helpdesk
https://www.wjgnet.com

© 2025 Baishideng Publishing Group Inc. All rights reserved.